- 
- Title: Retinal pigment epithelial cells reduce vascular leak and proliferation in<br>1 **Ferdinal neovessels<br>1 Short title: RPE cells reduce vascular leak in retinal neovessels<br>1 Simone Tzaridis<sup>1,2</sup> Edith Aquilar<sup>2</sup> Michael I**
- 2 **retinal neovessels<br>3 Short title: RPE cel<br>4 Simone Tzaridis<sup>1,2</sup>, E<br>5 Eade<sup>1,2</sup> Short title: RPE cells reduce vascular leak in retinal neovessels<br>3 Simone Tzaridis<sup>1,2</sup>, Edith Aguilar<sup>2</sup>, Michael I Dorrell<sup>1,3</sup>, Martin Friedlar<br>5 Eade<sup>1,2</sup><br><sup>4</sup> The Lowy Medical Research Institute La Jolla, California,** Simone Tzaridis<sup>1,2</sup>, Edith Aguilar<sup>2</sup>, Michael I Dorrell<sup>1,3</sup>, Martin Friedlander<sup>1,2</sup>
- $Eade<sup>1,2</sup>$
- Simone Tzaridis<sup>1,2</sup>, Edith Aguilar<sup>2</sup>, Michael I Dorrell<sup>1,3</sup>, Martin Friedlander<sup>1,2</sup>, Kevin T<br>Eade<sup>1,2</sup><br><sup>1</sup> The Lowy Medical Research Institute, La Jolla, California, USA<br><sup>2</sup> Department of Molecular Medicine. The Scripp 6<br>7<br>8 <sup>1</sup> The Lowy Medical Research Institute, La Jolla, California, USA
- <sup>1</sup> The Lowy Medical Research Institute, La Jolla, California, USA<br><sup>2</sup> Department of Molecular Medicine, The Scripps Research Instit<br>California, USA<br><sup>3</sup> Point Loma Nazarene University, San Diego, California, USA 2 <sup>2</sup> Department of Molecular Medicine, The Scripps Research Institute, La Jolla,<br>8 California, USA<br><sup>3</sup> Point Loma Nazarene University, San Diego, California, USA<br><sup>0</sup>
- 
- 8 California, USA<br>9 <sup>3</sup> Point Loma Na<br>0 <sup>3</sup> Point Loma Nazarene University, San Diego, California, USA <sup>9</sup> Point Loma Nazarene University, San Diego, California, USA<br>0<br>1
- 
- 
- 
- 11<br>12 --<br>12<br>13  $12<sup>12</sup>$
- 13
- --<br>13<br>14 14<br>15 14
- 
- 15<br>16 15
- --<br>16<br>17
- 16
- 
- 
- --<br>17<br>18 17
- 18
- 
- --<br>18<br>19 --<br>19 19

20 **Abstract**<br>21 Retinal pig<br>22 stress and<br>23 including Retinal pigment epithelial (RPE)-cells possess numerous functions and may respond to<br>22 stress and damage of the neuroretina. In different neurodegenerative diseases,<br>23 including age-related macular degeneration (AMD), re stress and damage of the neuroretina. In different neurodegenerative diseases,<br>including age-related macular degeneration (AMD), retinitis pigmentosa, and ma<br>telangiectasia type 2 (MacTel), RPE-cells have been shown to pro including age-related macular degeneration (AMD), retinitis pigmentosa, and macular<br>telangiectasia type 2 (MacTel), RPE-cells have been shown to proliferate and migrate<br>into the neuroretina, forming intraretinal pigment pl telangiectasia type 2 (MacTel), RPE-cells have been shown to proliferate and migrate<br>into the neuroretina, forming intraretinal pigment plaques. Though pigmentary changes<br>are associated with disease progression, it is not 26 are associated with disease progression, it is not known if their presence is protective or<br>27 detrimental. In this study, we evaluated the impact of pigment plaques on vascular<br>28 changes and disease progression in pat are associated with disease progression, it is not known if their presence is protective or<br>detrimental. In this study, we evaluated the impact of pigment plaques on vascular<br>changes and disease progression in patients wit detrimental. In this study, we evaluated the impact of pigment plaques on vascular<br>changes and disease progression in patients with macular telangiectasia type 2<br>(MacTel), an example of a progressive neurodegenerative reti changes and disease progression in patients with macular telangiectasia type 2<br>
(MacTel), an example of a progressive neurodegenerative retinal disease. We the<br>
studied underlying pathomechanisms using a mouse model mirror 29 (MacTel), an example of a progressive neurodegenerative retinal disease. We then<br>20 studied underlying pathomechanisms using a mouse model mirroring these changes<br>21 the very-low-density lipoprotein receptor mutant (VId studied underlying pathomechanisms using a mouse model mirroring these changes,<br>the very-low-density lipoprotein receptor mutant (VIdIr–/–) mouse.<br>In a retrospective, longitudinal study, we analyzed multimodal retinal imag the very-low-density lipoprotein receptor mutant (Vldlr–/–) mouse.<br>132 In a retrospective, longitudinal study, we analyzed multimodal retir<br>133 with MacTel and showed that pigment plaques were associated wi<br>14 vascular lea In a retrospective, longitudinal study, we analyzed multimodal retinal images of patients<br>with MacTel and showed that pigment plaques were associated with a decrease in<br>vascular leakage and stabilized neovascular growth. U with MacTel and showed that pigment plaques were associated with a decrease in<br>vascular leakage and stabilized neovascular growth. Using genetic approaches, we<br>analyzed changes in expression levels of relevant genes in the vascular leakage and stabilized neovascular growth. Using genetic approaches, we<br>analyzed changes in expression levels of relevant genes in the RPE and retinas of<br>VIdIr-/- mice during RPE-proliferation and migration. Our d analyzed changes in expression levels of relevant genes in the RPE and retinas of<br>36 VIdIr-/- mice during RPE-proliferation and migration. Our data indicated that RPE-ce<br>37 transitioned from an epithelial to a mesenchymal VIdIr-/- mice during RPE-proliferation and migration. Our data indicated that RPE-cells<br>transitioned from an epithelial to a mesenchymal state ("epithelial-mesenchymal<br>transition", EMT), proliferated and accumulated along transitioned from an epithelial to a mesenchymal state ("epithelial-mesenchymal<br>transition", EMT), proliferated and accumulated along neovessels. Using dextran<br>angiography and immunofluorescence, we demonstrated that the p transition", EMT), proliferated and accumulated along neovessels. Using dextran<br>angiography and immunofluorescence, we demonstrated that the perivascular<br>accumulation of RPE-cells reduced vascular leakage. Pharmacologic in 39 angiography and immunofluorescence, we demonstrated that the perivascular<br>20 accumulation of RPE-cells reduced vascular leakage. Pharmacologic inhibition<br>21 led to a decrease in pigment coverage and exacerbation of neov accumulation of RPE-cells reduced vascular leakage. Pharmacologic inhibition of EMT<br>led to a decrease in pigment coverage and exacerbation of neovascular growth and<br>exudation. led to a decrease in pigment coverage and exacerbation of neovascular growth and<br>
exudation.<br>
exudation. 42 exudation.



54

55 **Introduction**<br>56 Retinal pigme<br>57 stress and dain<br>58 including age-Retinal pigment epithelial (RPE)-cells possess numerous functions and may respond to<br>stress and damage of the neuroretina.[1] In different neurodegenerative diseases,<br>including age-related macular degeneration (AMD), retin stress and damage of the neuroretina.[1] In different neurodegenerative diseases,<br>including age-related macular degeneration (AMD), retinitis pigmentosa, and macu<br>telangiectasia type 2 (MacTel), RPE-cells have been propose including age-related macular degeneration (AMD), retinitis pigmentosa, and macular<br>telangiectasia type 2 (MacTel), RPE-cells have been proposed to proliferate and<br>migrate into the neuroretina, forming intraretinal pigment telangiectasia type 2 (MacTel), RPE-cells have been proposed to proliferate and<br>60 migrate into the neuroretina, forming intraretinal pigment plaques.[2-5] Increasing<br>61 evidence suggests that during this process, RPE-cell migrate into the neuroretina, forming intraretinal pigment plaques.[2-5] Increasing<br>
evidence suggests that during this process, RPE-cells transition from an epithelial<br>
mesenchymal state ("epithelial-mesenchymal transitio evidence suggests that during this process, RPE-cells transition from an epithelial to a<br>formal state ("epithelial-mesenchymal transition", EMT), granting these cells<br>mesenchymal properties such as the ability to prolifera mesenchymal state ("epithelial-mesenchymal transition", EMT), granting these cells<br>mesenchymal properties such as the ability to proliferate and migrate.[6, 7] Though<br>pigmentary changes are commonly associated with disease mesenchymal properties such as the ability to proliferate and migrate.[6, 7] Though<br>pigmentary changes are commonly associated with disease progression, their role is<br>not fully understood. This association could represent pigmentary changes are commonly associated with disease progression, their role is<br>form of fully understood. This association could represent a causative relationship whereb<br>form the pigmentary changes contribute to diseas not fully understood. This association could represent a causative relationship whereby<br>the pigmentary changes contribute to disease progression, pigmentary changes could<br>be protective from worsening disease, or pigmentati the pigmentary changes contribute to disease progression, pigmentary changes could<br>
be protective from worsening disease, or pigmentation could simply be an effect of other<br>
disease-causing retinal changes that are unrelat be protective from worsening disease, or pigmentation could simply be an effect of other<br>disease-causing retinal changes that are unrelated to disease progression.<br>MacTel is an example of a progressive, neurodegenerative r disease-causing retinal changes that are unrelated to disease progression.<br>
MacTel is an example of a progressive, neurodegenerative retinal disease t<br>
the central retina. Secondary vascular alterations are commonly observ MacTel is an example of a progressive, neurodegenerative retinal disease that affects<br>the central retina. Secondary vascular alterations are commonly observed.[8] Pigment<br>plaques are a frequent finding in MacTel and pigmen the central retina. Secondary vascular alterations are commonly observed.[8] Pigment<br>plaques are a frequent finding in MacTel and pigmented changes and vascular<br>alterations have been found to collocate.[3, 5] Early vascula plaques are a frequent finding in MacTel and pigmented changes and vascular<br>alterations have been found to collocate.[3, 5] Early vascular changes of the dis<br>include telangiectasia and increased vascular leakage, indicatin alterations have been found to collocate.[3, 5] Early vascular changes of the disease<br>include telangiectasia and increased vascular leakage, indicating a dysfunctional inne<br>blood-retina barrier.[8] With disease progression include telangiectasia and increased vascular leakage, indicating a dysfunctional inner<br>blood-retina barrier.[8] With disease progression, a shift of vessels from the deep retina<br>plexus to the outer retina as well as the f blood-retina barrier.[8] With disease progression, a shift of vessels from the deep retinal<br>plexus to the outer retina as well as the formation of retinal-choroidal anastomoses and<br>outer retinal neovascularization has been plexus to the outer retina as well as the formation of retinal-choroidal anastomoses and<br>outer retinal neovascularization has been described. These changes may precede the<br>formation of vision-threatening exudative subretin 76 outer retinal neovascularization has been described. These changes may precede the<br>17 formation of vision-threatening exudative subretinal neovascularization in some<br>17 formation of vision-threatening exudative subretin

77 formation of vision-threatening exudative subretinal neovascularization in some

cases,[9-12] and the origin of neovessels has been ascribed to the retinal rather than<br>the choroidal vasculature.[13-16] Recent imaging studies in MacTel proposed that the<br>formation of outer retinal neovascularization indu the choroidal vasculature.[13-16] Recent imaging studies in MacTel proposed that the<br>formation of outer retinal neovascularization induced proliferation of the RPE, upon<br>contact between the RPE and outer retinal vessels.[1 80 formation of outer retinal neovascularization induced proliferation of the RPE, upon<br>81 contact between the RPE and outer retinal vessels.[17] It has been supposed that F<br>82 cells then use these abnormal vessels as a sc 81 contact between the RPE and outer retinal vessels.[17] It has been supposed that RPE<br>82 cells then use these abnormal vessels as a scaffolding to migrate into inner retinal<br>83 layers, where they form dense pigmented pla cells then use these abnormal vessels as a scaffolding to migrate into inner retinal<br>layers, where they form dense pigmented plaques.[5] Their role during disease<br>progression and their impact on vascular changes, including layers, where they form dense pigmented plaques.[5] Their role during disease<br>progression and their impact on vascular changes, including vascular leakage a<br>proliferation, have not yet been evaluated. We hypothesized that progression and their impact on vascular changes, including vascular leakage and<br>proliferation, have not yet been evaluated. We hypothesized that the perivascular<br>accumulation of RPE-cells may stabilize vascular proliferat 85 proliferation, have not yet been evaluated. We hypothesized that the perivascular<br>86 accumulation of RPE-cells may stabilize vascular proliferation and reduce vascula<br>87 permeability.<br>88 The very-low-density lipoprotein accumulation of RPE-cells may stabilize vascular proliferation and reduce vascular<br>permeability.<br>The very-low-density lipoprotein receptor (VIdIr) mutant (VIdIr–/–) mouse represents<br>common model of subretinal neovasculariz 87 permeability.<br>88 The very-low-<br>89 common mod<br>90 characteristic 88 The very-low-density lipoprotein receptor (VIdIr) mutant (VIdIr–/–) mouse represents a<br>89 common model of subretinal neovascularization, and is used to study disease<br>80 characteristics of MacTel, retinal angiomatous pro common model of subretinal neovascularization, and is used to study disease<br>characteristics of MacTel, retinal angiomatous proliferation and other condition<br>As in MacTel, in VIdIr–/– mice, neovascular changes originate fro characteristics of MacTel, retinal angiomatous proliferation and other conditions.[18, 19]<br>91 As in MacTel, in VIdIr–/– mice, neovascular changes originate from the retinal<br>92 vasculature. Retinal vessels proliferate, grow 91 As in MacTel, in VIdIr–/– mice, neovascular changes originate from the retinal<br>92 vasculature. Retinal vessels proliferate, grow to the outer retina, and subseque<br>93 subretinal neovascularization. As the disease progres vasculature. Retinal vessels proliferate, grow to the outer retina, and subsequently form<br>subretinal neovascularization. As the disease progresses, mice show a proliferation of<br>RPE cells with accumulation along neovascular subretinal neovascularization. As the disease progresses, mice show a proliferation of<br>RPE cells with accumulation along neovascular tufts, followed by the migration of<br>pigmented cells along retinal vessels into the neuror RPE cells with accumulation along neovascular tufts, followed by the migration of<br>pigmented cells along retinal vessels into the neuroretina.[18, 20, 21] These event<br>mirror the key neovascular and pigmentation-related even pigmented cells along retinal vessels into the neuroretina.[18, 20, 21] These events<br>mirror the key neovascular and pigmentation-related events observed in MacTel and<br>other diseases with subretinal neovascularization, maki mirror the key neovascular and pigmentation-related events observed in MacTel and<br>other diseases with subretinal neovascularization, making the VIdIr-/- mouse an ideal<br>model to study these changes. other diseases with subretinal neovascularization, making the Vldlr-/- mouse an ideal<br>model to study these changes.<br>Maximization making the Vldlr-/- mouse an ideal 98 model to study these changes.<br>
These changes.<br>
The study these changes.

In this study, we aimed to (I) evaluate the role of pigment plaques on vascular changes<br>and disease progression in MacTel, and (II) study underlying disease mechanisms<br>using the VIdIr-/- mouse model mirroring these changes

and disease progression in MacTel, and (II) study underlying disease mechanisms<br>101 using the VIdIr-/- mouse model mirroring these changes.<br>102 First, we show in a longitudinal, retrospective study of eyes with MacTel that using the Vldlr-/- mouse model mirroring these changes.<br>102 First, we show in a longitudinal, retrospective study of ey<br>103 perivascular pigment accumulation was associated with r<br>104 decreased *de novo* formation of exuda 102 First, we show in a longitudinal, retrospective study of eyes with MacTel that<br>103 perivascular pigment accumulation was associated with reduced vascular lea<br>104 decreased *de novo* formation of exudative neovasculariz 103 perivascular pigment accumulation was associated with reduced vascular leakage and<br>104 decreased *de novo* formation of exudative neovascularization. We then explored<br>105 whether the observed associations were causally decreased *de novo* formation of exudative neovascularization. We then explored<br>
105 whether the observed associations were causally related and which mechanisms<br>
106 perivascular pigment accumulation in VIdIr-/- retinas. whether the observed associations were causally related and which mechanisms led to<br>106 perivascular pigment accumulation in VIdIr-/- retinas. We found an enrichment of EMT-<br>107 inducers and key mesenchymal markers in the 106 perivascular pigment accumulation in VIdIr-/- retinas. We found an enrichment of EMT-<br>
107 inducers and key mesenchymal markers in the RPE of VIdIr-/- mice. Pharmacologic<br>
108 inhibition of EMT-inducers led to decrease inducers and key mesenchymal markers in the RPE of VIdIr-/- mice. Pharmacologic<br>108 inhibition of EMT-inducers led to decreased perivascular pigment accumulation and<br>109 enhanced neovascular growth and exudation in the VId inhibition of EMT-inducers led to decreased perivascular pigment accumulation and<br>
109 enhanced neovascular growth and exudation in the VIdIr-/- model, indicating a<br>
110 protective effect of pigmentary changes on vascular enhanced neovascular growth and exudation in the VIdIr-/- model, indicating a<br>110 protective effect of pigmentary changes on vascular proliferation, mitigating vas<br>111 leak and proliferation. Based on our findings, we prop protective effect of pigmentary changes on vascular proliferation, mitigating vascular<br>111 leak and proliferation. Based on our findings, we propose that EMT of the RPE, follov<br>112 by proliferation, migration and perivascu 111 leak and proliferation. Based on our findings, we propose that EMT of the RPE, followed<br>
112 by proliferation, migration and perivascular accumulation may function as a "natural<br>
113 repair mechanism", exerting benefic by proliferation, migration and perivascular accumulation may function as a "natural<br>113 repair mechanism", exerting beneficial, anti-angiogenic and anti-exudative effects or<br>114 diseased retina. As such, we conclude that 113 repair mechanism", exerting beneficial, anti-angiogenic and anti-exudative effects on the<br>114 diseased retina. As such, we conclude that interfering with these mechanisms may have<br>115 detrimental effects on the course diseased retina. As such, we conclude that interfering with these mechanisms may have<br>detrimental effects on the course of the disease and should thus be avoided.<br>**Results**<br>Results<br>*Results*<br>*Perivascular accumulation of n* 

detrimental effects on the course of the disease and should thus be avoided.<br>116 **Results**<br>117 *Perivascular accumulation of pigment is associated with decreased vascular*<br>118 *eves with MacTel To investigate the impact o* 116 **Results**<br>117 *Perivasc*<br>118 eyes witl<br>119 vessel le Perivascular accumulation of pigment is associated with decreased vascular leakage in<br>118 eyes with MacTel. To investigate the impact of perivascular pigment accumulation on<br>119 vessel leakage and proliferation in MacTel, eyes with MacTel. To investigate the impact of perivascular pigment accumulation on<br>119 vessel leakage and proliferation in MacTel, we compared the longitudinal courses of<br>120 eyes with and eyes without pigment plaque *de* vessel leakage and proliferation in MacTel, we compared the longitudinal courses of<br>120 eyes with and eyes without pigment plaque *de novo* formation. A total of 1216 eyes<br>121 from 608 patients of 12 study centers were eva 120 eyes with and eyes without pigment plaque *de novo* formation. A total of 1216 eyes<br>121 from 608 patients of 12 study centers were evaluated. 69 eyes from 69 patients (me 121 from 608 patients of 12 study centers were evaluated. 69 eyes from 69 patients (mean

6

age 61.9 (range 53-71) years) were included and reviewed over a mean period of 41.6<br>months (range 24-60). 35 eyes (51%) showed a *de novo* development of pigmentary<br>changes, and 34 eyes did not. Pigment plaques predominant months (range 24-60). 35 eyes (51%) showed a *de novo* development of pigmentary<br>124 changes, and 34 eyes did not. Pigment plaques predominantly accumulated along<br>125 vessels within the temporal parafovea (ETDRS subfield 5 214 changes, and 34 eyes did not. Pigment plaques predominantly accumulated along<br>125 vessels within the temporal parafovea (ETDRS subfield 5), usually sparing the fove<br>126 (Additional figure 1). Rarely, an extension of ch vessels within the temporal parafovea (ETDRS subfield 5), usually sparing the fovea<br>126 (Additional figure 1). Rarely, an extension of changes to the superior, inferior, or nasa<br>127 parafovea (ETDRS subfields 2, 4, 3) was

126 (Additional figure 1). Rarely, an extension of changes to the superior, inferior, or nasal<br>127 parafovea (ETDRS subfields 2, 4, 3) was observed.<br>128 Longitudinal courses of eyes developing pigmented lesions differed fr parafovea (ETDRS subfields 2, 4, 3) was observed.<br>128 Longitudinal courses of eyes developing pigmented<br>129 A decrease in fluorescein leakage and stabilization of<br>130 all but one eye with pigment plaques. The observed Longitudinal courses of eyes developing pigmented lesions differed from those without.<br>
129 A decrease in fluorescein leakage and stabilization of vessel proliferation was noted in<br>
130 all but one eye with pigment plaques 129 A decrease in fluorescein leakage and stabilization of vessel proliferation was noted in<br>130 all but one eye with pigment plaques. The observed effects were, however, focal and<br>131 limited to vessels covered with pigme all but one eye with pigment plaques. The observed effects were, however, focal and<br>131 limited to vessels covered with pigment. In these eyes, vessels lacking pigment plaqu<br>132 showed stable, or rarely, increased leakage limited to vessels covered with pigment. In these eyes, vessels lacking pigment plaques<br>showed stable, or rarely, increased leakage (observed in the nasal parafovea (ETDRS<br>subfield 3) of 4/35 eyes; see figure 1). Notably, showed stable, or rarely, increased leakage (observed in the nasal parafovea (ETDRS<br>subfield 3) of 4/35 eyes; see figure 1). Notably, coverage of vessels with pigment was<br>associated with a decrease in fluorescein leakage b subfield 3) of 4/35 eyes; see figure 1). Notably, coverage of vessels with pigment was<br>associated with a decrease in fluorescein leakage both in the early and late phase of<br>fundus fluorescein angiography (FFA), suggesting associated with a decrease in fluorescein leakage both in the early and late phase of<br>
fundus fluorescein angiography (FFA), suggesting a sealing rather than a mere<br>
shadowing effect associated with perivascular pigment ac fundus fluorescein angiography (FFA), suggesting a sealing rather than a mere<br>
shadowing effect associated with perivascular pigment accumulation. In eyes wi<br>
pigmentary changes, an increase in vascular leakage (in 16/34 e shadowing effect associated with perivascular pigment accumulation. In eyes without<br>pigmentary changes, an increase in vascular leakage (in 16/34 eyes [47%]) or stable<br>leakage (in 18/34 eyes [53%]; table 1) was observed. P 137 pigmentary changes, an increase in vascular leakage (in 16/34 eyes [47%]) or stable<br>138 leakage (in 18/34 eyes [53%]; table 1) was observed. Proliferation of vessels and<br>139 increase in leakage were primarily observed 138 leakage (in 18/34 eyes [53%]; table 1) was observed. Proliferation of vessels and<br>
139 increase in leakage were primarily observed within the temporal parafovea (ETDR<br>
140 subfield 5). Exemplary longitudinal courses ar increase in leakage were primarily observed within the temporal parafovea (ETDRS<br>subfield 5). Exemplary longitudinal courses are illustrated in figures 1 and 2.<br>Exudative subretinal neovascularization is considered a sever

subfield 5). Exemplary longitudinal courses are illustrated in figures 1 and 2.<br>141 Exudative subretinal neovascularization is considered a severe, vision-threat<br>142 complication of MacTel, and is associated with severe va Exudative subretinal neovascularization is considered a severe, vision-threatening<br>
complication of MacTel, and is associated with severe vascular leakage. The de no<br>
formation of exudative subretinal neovascular membranes 142 complication of MacTel, and is associated with severe vascular leakage. The de novo<br>143 formation of exudative subretinal neovascular membranes was less frequently observe<br>144 in eyes with compared to eyes without pigm 143 formation of exudative subretinal neovascular membranes was less frequently observed<br>
144 in eyes with compared to eyes without pigment plaques (in 1/35 [3%] eyes vs 7/34<br>
17 144 in eyes with compared to eyes without pigment plaques (in 1/35 [3%] eyes vs 7/34

145 [21%]; Fisher's exact test, p=0.0275). Table 1 gives an overview of the clinical findings<br>146 in this study cohort.<br>147 In summary, patients with MacTel showed (I) an accumulation of pigment plaques along<br>148 abnormal 146 in this study cohort.<br>147 In summary, patient:<br>148 abnormal retinal and<br>149 associated with the 147 In summary, patients with MacTel showed (I) an accumulation of pigment plaques along<br>
148 abnormal retinal and subretinal vessels, (II) a decrease in vascular leakage that was<br>
149 associated with the development of pi abnormal retinal and subretinal vessels, (II) a decrease in vascular leakage that was<br>associated with the development of pigment plaques, and (III) a decrease in exudativ<br>subretinal neovascularization associated with the p associated with the development of pigment plaques, and (III) a decrease in exudative<br>subretinal neovascularization associated with the presence of pigment plaques. Based<br>on our findings in patients with MacTel, we hypothe subretinal neovascularization associated with the presence of pigment plaques. Based<br>on our findings in patients with MacTel, we hypothesized that (I) proliferating vessels<br>may trigger the proliferation and perivascular ac on our findings in patients with MacTel, we hypothesized that (I) proliferating vessels<br>
152 may trigger the proliferation and perivascular accumulation of pigment. (II) Pigment<br>
153 plaques may be formed by RPE cells that may trigger the proliferation and perivascular accumulation of pigment. (II) Pigment<br>153 plaques may be formed by RPE cells that undergo EMT, proliferate, migrate and<br>154 accumulate along proliferating vessels. (III) Periv plaques may be formed by RPE cells that undergo EMT, proliferate, migrate and<br>accumulate along proliferating vessels. (III) Perivascular pigment plaques may de<br>vascular leakage and stabilize vessel proliferation, thus havi 154 accumulate along proliferating vessels. (III) Perivascular pigment plaques may decrease<br>155 vascular leakage and stabilize vessel proliferation, thus having a beneficial effect on the<br>156 diseased retina.<br>157 To test t

vascular leakage and stabilize vessel proliferation, thus having a beneficial effect on the<br>156 diseased retina.<br>157 To test these hypotheses, and to further evaluate disease mechanisms leading to<br>158 perivascular pigment 156 diseased retina.<br>157 To test these hyp<br>158 perivascular pigr<br>159 model. Similar to 157 To test these hypotheses, and to further evaluate disease mechanisms leading to<br>158 perivascular pigment accumulation, we studied related changes in the VIdIr-/- mou<br>159 model. Similar to eyes with MacTel, the VIdIr-/-158 perivascular pigment accumulation, we studied related changes in the VIdIr-/- mouse<br>
159 model. Similar to eyes with MacTel, the VIdIr-/- mouse model shows a proliferation of<br>
160 retinal vessels, formation of retinalmodel. Similar to eyes with MacTel, the VldIr-/- mouse model shows a proliferation of<br>160 retinal vessels, formation of retinal-choroidal anastomoses and subretinal<br>161 neovascularization. With disease progression, RPE-cel 160 retinal vessels, formation of retinal-choroidal anastomoses and subretinal<br>161 neovascularization. With disease progression, RPE-cells proliferate and a<br>162 along subretinal neovessels, and subsequently migrate along r neovascularization. With disease progression, RPE-cells proliferate and accumulate<br>162 along subretinal neovessels, and subsequently migrate along retinal vessels into the<br>163 neuroretina.[18, 19, 21]<br>164 Proliferating ret along subretinal neovessels, and subsequently migrate along retinal vessels into the<br>163 neuroretina.[18, 19, 21]<br>164 Proliferating retinal vessels trigger perivascular pigment accumulation.<br>165 Ne first set out to investi

163 neuroretina.[18, 19, 21]<br>164 *Proliferating retinal vess*<br>165 We first set out to invest<br>166 **perivascular accumulati**o Proliferating retinal vessels trigger perivascular pigment accumulation.<br>165 We first set out to investigate whether vascular proliferation triggers the<br>166 perivascular accumulation of pigment. In the VIdIr-/- mouse model 165 We first set out to investigate whether vascular proliferation triggers the proliferation and<br>166 perivascular accumulation of pigment. In the VIdIr-/- mouse model, retinal vessels begin<br>166 perivascular accumulation o 166 perivascular accumulation of pigment. In the VldIr-/- mouse model, retinal vessels begin<br>8



190 latter were, however, overall smaller and less dense compared to lesions lacking a-SMA<br>191 expression, indicating a transitional, possibly less mature stage of these lesions<br>192 (Additional figure 2).<br>193 *RPE-cells un* expression, indicating a transitional, possibly less mature stage of these lesions<br>192 (Additional figure 2).<br>193 RPE-cells undergo EMT in VIdIr-/- retinas.<br>194 Linder physiologic conditions the RPE is formed by a monolaye

192 (Additional figure 2).<br>193 RPE-cells undergo E<br>194 Under physiologic co<br>195 Disintegration of the 193 *RPE-cells undergo EMT in VIdIr-/- retinas.*<br>194 Under physiologic conditions, the RPE is fo<br>195 Disintegration of the RPE monolayer and p<br>196 been described in different degenerative re Under physiologic conditions, the RPE is formed by a monolayer of polarized cells.<br>
Disintegration of the RPE monolayer and proliferation and migration of RPE-cells has<br>
been described in different degenerative retinal dis Disintegration of the RPE monolayer and proliferation and migration of RPE-cells have<br>
196 been described in different degenerative retinal diseases, and have been attributed to<br>
197 RPE cells transitioning from an epithel been described in different degenerative retinal diseases, and have been attributed to<br>197 RPE cells transitioning from an epithelial to a mesenchymal state.[7] To test whether<br>198 RPE cells underwent EMT in the Vldlr-/- m 197 RPE cells transitioning from an epithelial to a mesenchymal state.[7] To test whether<br>198 RPE cells underwent EMT in the Vldlr-/- mouse model, we compared gene expressio<br>199 levels of known EMT-related genes in the RPE 198 RPE cells underwent EMT in the Vldlr-/- mouse model, we compared gene expression<br>199 levels of known EMT-related genes in the RPE of Vldlr-/- mice and control Vldlr-/+<br>100 littermates at P42. At this timepoint, RPE cel levels of known EMT-related genes in the RPE of Vldlr–/– mice and control Vldlr-/+<br>200 littermates at P42. At this timepoint, RPE cells have been shown to proliferate and<br>201 accumulate along subretinal neovessels and star 200 littermates at P42. At this timepoint, RPE cells have been shown to proliferate and<br>201 accumulate along subretinal neovessels and start migrating along retinal vessels in<br>202 the neuroretina.[18, 19, 21] Using qPCR ar accumulate along subretinal neovessels and start migrating along retinal vessels into<br>
202 the neuroretina.[18, 19, 21] Using qPCR arrays, we found an enrichment of genes<br>
203 coding for EMT pathways (SNAIL1/2) and differe 202 the neuroretina.[18, 19, 21] Using qPCR arrays, we found an enrichment of genes<br>
203 coding for EMT pathways (SNAIL1/2) and different mesenchymal markers (vimenti<br>
204 fibronectin, N-cadherin) in the RPE of VIdIr-/- mi coding for EMT pathways (SNAIL1/2) and different mesenchymal markers (vimentin,<br>
204 fibronectin, N-cadherin) in the RPE of VIdIr-/- mice. Genes coding for epithelial marke<br>
205 (beta-catenin, E-cadherin, zonula occludens-204 fibronectin, N-cadherin) in the RPE of VIdIr-/- mice. Genes coding for epithelial markers<br>205 (beta-catenin, E-cadherin, zonula occludens-1 [ZO-1]), on the other hand, were<br>206 decreased (Figure 3B), indicating that RP 205 (beta-catenin, E-cadherin, zonula occludens-1 [ZO-1]), on the other hand, were<br>206 decreased (Figure 3B), indicating that RPE cells underwent EMT in this model.<br>207 Next, we tested mRNA expression levels of known induc decreased (Figure 3B), indicating that RPE cells underwent EMT in this model.<br>207 Next, we tested mRNA expression levels of known inducers of EMT in the retina<br>208 RPE of VIdIr-/- mice. The highest differences between VIdI 207 Next, we tested mRNA expression levels of known inducers of EMT in the retinas and<br>208 RPE of VldIr-/- mice. The highest differences between VldIr-/- and heterozygous contr<br>209 littermates were found in fibroblast grow RPE of Vldlr-/- mice. The highest differences between Vldlr-/- and heterozygous control<br>209 littermates were found in fibroblast growth factor-2 (FGF2), which was increased 4-fold,<br>210 and in tumor-necrosis factor-alpha (T 209 littermates were found in fibroblast growth factor-2 (FGF2), which was increased 4-fold,<br>210 and in tumor-necrosis factor-alpha (TNFa), which was increased 2.5-fold. FGF2 is a<br>211 known driver of EMT that, among other 210 and in tumor-necrosis factor-alpha (TNFa), which was increased 2.5-fold. FGF2 is a<br>211 known driver of EMT that, among other factors, has been described to play a role in<br>212 inducing EMT in RPE cells in proliferative 211 known driver of EMT that, among other factors, has been described to play a role in<br>212 inducing EMT in RPE cells in proliferative vitreoretinopathy (PVR)[24]. FGF2 is also 212 inducing EMT in RPE cells in proliferative vitreoretinopathy (PVR)[24]. FGF2 is also<br>inducing EMT in RPE cells in proliferative vitreoretinopathy (PVR)[24]. FGF2 is also<br>

213 known to play a role in inducing subretinal fibrosis, and has been shown to have pro-<br>214 angiogenic properties.[25, 26] TNFa is a proinflammatory cytokine and a known indu-<br>215 of EMT in RPE cells.[7, 27] Elevated lev 214 angiogenic properties.[25, 26] TNFa is a proinflammatory cytokine and a known inducer<br>215 of EMT in RPE cells.[7, 27] Elevated levels of TNFa have been detected in vitreous<br>216 samples and epiretinal membranes of patie 215 of EMT in RPE cells.[7, 27] Elevated levels of TNFa have been detected in vitreous<br>216 samples and epiretinal membranes of patients with PVR[28].[27, 29] *In vitro*, TNFa h<br>217 been shown to induce RPE cells to upregul 216 samples and epiretinal membranes of patients with PVR[28].[27, 29] *In vitro*, TNFa has<br>217 been shown to induce RPE cells to upregulate EMT markers and mesenchymal key<br>218 molecules.[30] Increased expression levels of been shown to induce RPE cells to upregulate EMT markers and mesenchymal key<br>218 molecules.[30] Increased expression levels of TNF have previously been found in the<br>219 retinas of VIdIr-/- mice, and in particular at the le molecules.[30] Increased expression levels of TNF have previously been found in the<br>
219 retinas of VIdIr-/- mice, and in particular at the level of the deep retinal plexus.[22]<br>
220 Perivascular pigment decreases neovascu retinas of Vldlr-/- mice, and in particular at the level of the deep retinal plexus.[22]<br>220 Perivascular pigment decreases neovascular leakage and proliferation in Vldlr-/- n<br>221 Similar to eyes with MacTel, we found that *Perivascular pigment decreases neovascular leakage and proliferation in Vldlr-/- retinas.*<br>221 Similar to eyes with MacTel, we found that in the Vldlr-/- mouse model vessels covered<br>222 with pigment showed reduced dextran 221 Similar to eyes with MacTel, we found that in the VIdIr-/- mouse model vessels covered<br>222 with pigment showed reduced dextran leakage compared to vessels not covered with<br>223 pigment (Figure 3C). Perivascular pigment with pigment showed reduced dextran leakage compared to vessels not covered with<br>pigment (Figure 3C). Perivascular pigment plaques expressed zonula occludens-1 (ZC<br>224 1), indicating the formation of tight junctions around 223 pigment (Figure 3C). Perivascular pigment plaques expressed zonula occludens-1 (ZO-<br>224 1), indicating the formation of tight junctions around proliferating vessels, thereby<br>225 possibly reducing vascular leakage (Figu 224 1), indicating the formation of tight junctions around proliferating vessels, thereby<br>225 possibly reducing vascular leakage (Figure 3D). Furthermore, on OCT, VIdIr-/- mior<br>226 showed hyper-reflective changes at the le possibly reducing vascular leakage (Figure 3D). Furthermore, on OCT, VIdIr-/- mice<br>
showed hyper-reflective changes at the level of the outer retina/ RPE that resemble<br>
alterations observed in MacTel (Figure 3-E), which ha 226 showed hyper-reflective changes at the level of the outer retina/ RPE that resemble<br>227 alterations observed in MacTel (Figure 3-E), which have been proposed to represen<br>228 outer retinal neovascularization and prolife alterations observed in MacTel (Figure 3-E), which have been proposed to represent<br>
outer retinal neovascularization and proliferating RPE-cells.[17] Next, we set out to<br>
investigate whether inhibiting EMT of the RPE may i 228 outer retinal neovascularization and proliferating RPE-cells.[17] Next, we set out to<br>
229 investigate whether inhibiting EMT of the RPE may impact neovascular leakage and<br>
230 proliferation in the VIdIr–/– model. Mice 229 investigate whether inhibiting EMT of the RPE may impact neovascular leakage and<br>230 proliferation in the VIdIr–/– model. Mice treated with neutralizing antibodies against<br>231 FGF2 or TNFa from P21 to P42 showed a sign proliferation in the Vldlr–/– model. Mice treated with neutralizing antibodies against<br>231 FGF2 or TNFa from P21 to P42 showed a significant increase in vascular leakage a<br>232 in the size of neovascular complexes at P42 in 231 FGF2 or TNFa from P21 to P42 showed a significant increase in vascular leakage and<br>232 in the size of neovascular complexes at P42 in comparison to IgG-treated control<br>233 animals (Figure 4A-C). Vascular leakage and pe 232 in the size of neovascular complexes at P42 in comparison to IgG-treated control<br>233 animals (Figure 4A-C). Vascular leakage and perivascular pigment accumulation<br>234 showed a negative correlation in both treated and c 233 animals (Figure 4A-C). Vascular leakage and perivascular pigment accumulation<br>234 showed a negative correlation in both treated and control animals (Figure 4D). 234 showed a negative correlation in both treated and control animals (Figure 4D).<br>
And the control animals (Figure 4D).

11

- 
- 235 To test whether the observed morphological changes were associated with the inhibition<br>236 of EMT, we compared gene expression levels of EMT-related genes in the RPE of<br>237 VIdIr–/– mice treated with FGF2, TNFa or cont 236 of EMT, we compared gene expression levels of EMT-related genes in the RPE of<br>237 VIdIr–/– mice treated with FGF2, TNFa or control IgG. While no changes were obse<br>238 for EMT pathways, genes coding for epithelial marke VIdIr–/– mice treated with FGF2, TNFa or control IgG. While no changes were observed<br>for EMT pathways, genes coding for epithelial markers were enriched, and<br>mesenchymal markers were decreased in animals treated with FGF2
- 
- 
- 
- for EMT pathways, genes coding for epithelial markers were enriched, and<br>239 mesenchymal markers were decreased in animals treated with FGF2 or TN<br>240 indicating the inhibition of EMT (Figure 4E).<br>241 In summary, we sugges mesenchymal markers were decreased in animals treated with FGF2 or TNFa,<br>240 indicating the inhibition of EMT (Figure 4E).<br>241 In summary, we suggest that the perivascular accumulation of RPE-cells may s<br>242 neovascular pr
- 241 In summary, we suggest that the perivascular accumulation of RPE-cells may stabilize<br>242 neovascular proliferation and leakage, thereby exerting a beneficial, protective effect on<br>243 the diseased retina. Figure 5 summ 242 neovascular proliferation and leakage, thereby exerting a beneficial, protective effect on<br>
243 the diseased retina. Figure 5 summarizes the herein proposed mechanisms in a<br>
244 schematic illustration.<br>
245 Discussion
- indicating the inhibition of EMT (Figure 4E).<br>241 In summary, we suggest that the perivascular<br>242 neovascular proliferation and leakage, there<br>243 the diseased retina. Figure 5 summarizes th the diseased retina. Figure 5 summarizes the herein proposed mechanisms in a<br>244 schematic illustration.<br>245 **Discussion**<br>246 Pigment plaques can be found in different retinal diseases involving vascular pat
- 

244 schematic illustration.<br>245 **Discussion**<br>246 Pigment plaques can b<br>247 and neurodegeneratio 245 **Discussion**<br>246 Pigment plac<br>247 and neurode<br>248 accumulating Pigment plaques can be found in different retinal diseases involving vascular pathology<br>
247 and neurodegeneration. The origin of these changes has been attributed to RPE-cells,<br>
248 accumulating along subretinal and retin 247 and neurodegeneration. The origin of these changes has been attributed to RPE-cells,<br>248 accumulating along subretinal and retinal vessels, and migrating along vascular<br>249 structures into the neuroretina.[3, 20] The r 248 accumulating along subretinal and retinal vessels, and migrating along vascular<br>249 structures into the neuroretina.[3, 20] The role these changes may play during di<br>250 progression is, however, not yet understood. In 249 structures into the neuroretina.[3, 20] The role these changes may play during disease<br>250 progression is, however, not yet understood. In this study, we sought to evaluate the<br>251 impact of perivascular pigment plaque progression is, however, not yet understood. In this study, we sought to evaluate the<br>
251 impact of perivascular pigment plaques on the progression of vascular changes in ey<br>
252 with MacTel. We observed an association of 251 impact of perivascular pigment plaques on the progression of vascular changes in eyes<br>252 with MacTel. We observed an association of perivascular pigment with a focal decrease<br>253 in vessel permeability, and stabilizat with MacTel. We observed an association of perivascular pigment with a focal decrease<br>253 in vessel permeability, and stabilization of vessel proliferation. The development of<br>254 exudative subretinal neovascular complexes in vessel permeability, and stabilization of vessel proliferation. The development of<br>254 exudative subretinal neovascular complexes was observed less frequently in eyes<br>255 compared to eyes without pigment plaque formatio exudative subretinal neovascular complexes was observed less frequently in eyes with<br>
255 compared to eyes without pigment plaque formation. In the literature, differing numbers<br>
256 describing potential associations of pi compared to eyes without pigment plaque formation. In the literature, differing numbers<br>describing potential associations of pigment plaques with subretinal neovascularization<br>in MacTel have been reported. While Leung et a 256 describing potential associations of pigment plaques with subretinal neovascularization<br>257 in MacTel have been reported. While Leung et al. found that in about 25% of<br>257 1. 257 in MacTel have been reported. While Leung et al. found that in about 25% of

neovascular eyes, subretinal neovascularization coincided with or preceded pigmentary<br>
changes[5], Engelbrecht et al observed that pigmented lesions preceded the<br>
development of neovascular membranes in all cases (in 11/11 changes[5], Engelbrecht et al observed that pigmented lesions preceded the<br>development of neovascular membranes in all cases (in 11/11 eyes).[14] Mel<br>reported the *de novo*-development of neovascularization in equal number development of neovascular membranes in all cases (in 11/11 eyes).[14] Meleth et al<br>
261 reported the *de novo*-development of neovascularization in equal numbers of eyes wit<br>
262 and without preexistent pigmentations, res reported the *de novo*-development of neovascularization in equal numbers of eyes with<br>and without preexistent pigmentations, respectively.[31] Differences between our data<br>and previous reports may be explained by differin 262 and without preexistent pigmentations, respectively.[31] Differences between our data<br>263 and previous reports may be explained by differing definitions of "neovascularization"<br>264 and "exudation", based on distinct im 263 and previous reports may be explained by differing definitions of "neovascularization"<br>264 and "exudation", based on distinct imaging modalities, and differing in- and exclusion<br>265 criteria, resulting in study populat 264 and "exudation", based on distinct imaging modalities, and differing in- and exclusion<br>265 criteria, resulting in study populations with varying disease stages, baseline<br>266 characteristics and observational periods. M criteria, resulting in study populations with varying disease stages, baseline<br>
characteristics and observational periods. More recent studies evaluating loi<br>
OCT-A data found that the formation of outer retinal neovascula characteristics and observational periods. More recent studies evaluating longitudinal<br>267 CCT-A data found that the formation of outer retinal neovascularization preceded<br>268 perivascular pigment accumulation in all cases 267 OCT-A data found that the formation of outer retinal neovascularization preceded<br>268 perivascular pigment accumulation in all cases.[32] Based on their findings on<br>269 multimodal retinal imaging, Mueller et al suggeste perivascular pigment accumulation in all cases.[32] Based on their findings on<br>multimodal retinal imaging, Mueller et al suggested that outer retinal neovascul<br>induced proliferation of the RPE, once retinal vessels get in multimodal retinal imaging, Mueller et al suggested that outer retinal neovascularization<br>
induced proliferation of the RPE, once retinal vessels get in contact with the RPE[17], a<br>
finding that is similar to previous obse induced proliferation of the RPE, once retinal vessels get in contact with the RPE[17], a<br>271 finding that is similar to previous observations in VIdIr-/- mice and other models.[18, 19,<br>272 21, 33] Our results are in line 271 finding that is similar to previous observations in Vldlr-/- mice and other models.[18, 19,<br>272 21, 33] Our results are in line with these later findings of neovascularization preceding<br>273 pigmentation and indicate th 272 21, 33] Our results are in line with these later findings of neovascularization preceding<br>
273 pigmentation and indicate that perivascular pigment accumulation is a focal process,<br>
274 possibly triggered by vascular le pigmentation and indicate that perivascular pigment accumulation is a focal process,<br>possibly triggered by vascular leakage and proliferation, and may represent a "repair<br>mechanism" of the disrupted RPE. Furthermore, our r possibly triggered by vascular leakage and proliferation, and may represent a "repair<br>mechanism" of the disrupted RPE. Furthermore, our results may indicate that pigmen<br>plaques could be used as a biomarker to predict neova 275 mechanism" of the disrupted RPE. Furthermore, our results may indicate that pigment<br>276 plaques could be used as a biomarker to predict neovascular exudation and vascular<br>277 stabilization, respectively. Prospective, l plaques could be used as a biomarker to predict neovascular exudation and vascular<br>277 stabilization, respectively. Prospective, longitudinal studies are needed to verify our<br>278 findings.<br>279 The reason why only a subset 277 stabilization, respectively. Prospective, longitudinal studies are needed to verify our<br>278 findings.<br>289 The reason why only a subset of MacTel patients develop pigment plaques currently<br>280 Fremains obscure and warra

278 findings.<br>279 The reas<br>280 remains 279 The reason why only a subset of MacTel patients develop pigment plaques currently<br>280 Fremains obscure and warrants further studies. Limited observational periods and pational<br>280 280 remains obscure and warrants further studies. Limited observational periods and patient 13<br>13

numbers might have confounded our findings, representing potential limitations of this<br>282 study.<br>70 study underlying disease mechanisms, we evaluated related pigmentary and<br>284 vascular changes in the Vldlr-/- mouse model 282 study.<br>283 To stud<br>284 vascula<br>285 plaque To study underlying disease mechanisms, we evaluated related pigmentary and<br>
284 vascular changes in the VIdIr-/- mouse model. We showed that perivascular pigm<br>
285 plaques expressed similar markers as previously described vascular changes in the VIdIr-/- mouse model. We showed that perivascular pigment<br>plaques expressed similar markers as previously described in postmortem retinal<br>specimens of eyes with MacTel and other diseases, verifying plaques expressed similar markers as previously described in postmortem retinal<br>286 specimens of eyes with MacTel and other diseases, verifying that these changes<br>287 formed by RPE-cells.[3, 20] We confirmed that pigment a specimens of eyes with MacTel and other diseases, verifying that these changes are<br>
1287 formed by RPE-cells.[3, 20] We confirmed that pigment accumulation was associated<br>
1288 with a decrease in vessel leakage in the VIdI 287 formed by RPE-cells.[3, 20] We confirmed that pigment accumulation was associated<br>288 with a decrease in vessel leakage in the VIdIr-/- model. Our findings indicate that<br>289 perivascular pigment plaques may form tight with a decrease in vessel leakage in the Vldlr-/- model. Our findings indicate that<br>perivascular pigment plaques may form tight junctions around proliferating vessel<br>indicated by ZO-1 localization, thereby reducing vascula perivascular pigment plaques may form tight junctions around proliferating vessels, as<br>
290 indicated by ZO-1 localization, thereby reducing vascular leakage and stabilizing<br>
291 neovascular growth. A similar effect of pig 290 indicated by ZO-1 localization, thereby reducing vascular leakage and stabilizing<br>291 neovascular growth. A similar effect of pigment plaques on vessel permeability ha<br>292 been previously reported by Jaissle et al, whe 291 neovascular growth. A similar effect of pigment plaques on vessel permeability has<br>292 been previously reported by Jaissle et al, where migrating RPE-cells were observed<br>293 form tight junctions with vascular endotheli been previously reported by Jaissle et al, where migrating RPE-cells were observed to<br>
form tight junctions with vascular endothelial cells, thus sealing retinal vessels in a<br>
mouse model for retinitis pigmentosa.[33]<br>
Whi

293 form tight junctions with vascular endothelial cells, thus sealing retinal vessels in a<br>294 mouse model for retinitis pigmentosa.[33]<br>295 While dense pigment plaques within the neuroretina and subretinal space of Vldlr mouse model for retinitis pigmentosa.[33]<br>295 While dense pigment plaques within the no<br>296 mice showed a focal expression of ZO-1, g<br>297 marker were downregulated in the RPE of 295 While dense pigment plaques within the neuroretina and subretinal space of Vldlr-/-<br>296 mice showed a focal expression of ZO-1, genes coding for the same epithelial cell<br>297 marker were downregulated in the RPE of Vldl mice showed a focal expression of ZO-1, genes coding for the same epithelial cell<br>
297 marker were downregulated in the RPE of VIdIr-/- mice, indicating a broader loss of<br>
298 cell contacts and epithelial cell state. This 297 marker were downregulated in the RPE of VIdIr-/- mice, indicating a broader loss of cell-<br>298 cell contacts and epithelial cell state. This suggests a loss of adhesion in the general<br>299 RPE monolayer, perhaps indicati cell contacts and epithelial cell state. This suggests a loss of adhesion in the general<br>
RPE monolayer, perhaps indicative of cells undergoing transition to a more migratory<br>
phenotype. Taken together, these findings migh RPE monolayer, perhaps indicative of cells undergoing transition to a more migratory<br>
200 phenotype. Taken together, these findings might indicate that RPE-cells undergo EMT<br>
201 proliferate and accumulate along subretinal phenotype. Taken together, these findings might indicate that RPE-cells undergo EMT,<br>proliferate and accumulate along subretinal and retinal vessels. Once migrating RPE-<br>cells have found their new position, they may develo 301 proliferate and accumulate along subretinal and retinal vessels. Once migrating RPE-<br>302 cells have found their new position, they may develop cell-cell contacts with neighbori<br>303 RPE-cells, forming dense plaques arou cells have found their new position, they may develop cell-cell contacts with neighboring<br>303 RPE-cells, forming dense plaques around the vessels, and possibly transition back to<br>14 303 RPE-cells, forming dense plaques around the vessels, and possibly transition back to

304 an epithelial state ("mesenchymal-epithelial transition", MET). Similar mechanisms have<br>305 been previously described to occur during cancer metastasis and organ<br>306 morphogenesis.[34, 35] The hypothesis that RPE cells been previously described to occur during cancer metastasis and organ<br>306 morphogenesis.[34, 35] The hypothesis that RPE cells undergo EMT, for<br>307 in the VIdIr-/- model is further supported by the differences we found in morphogenesis.[34, 35] The hypothesis that RPE cells undergo EMT, followed by MET,<br>in the VIdIr-/- model is further supported by the differences we found in the expression<br>of epithelial and mesenchymal markers in VIdIr-/ in the Vldlr-/- model is further supported by the differences we found in the expression<br>308 of epithelial and mesenchymal markers in Vldlr-/- mice compared to previous reports in<br>309 MacTel. In MacTel, intraretinal pigmen 308 of epithelial and mesenchymal markers in Vldlr-/- mice compared to previous reports in<br>309 MacTel. In MacTel, intraretinal pigment plaques were found to only express the<br>310 epithelial marker CK18, while lacking any me MacTel. In MacTel, intraretinal pigment plaques were found to only express the<br>
epithelial marker CK18, while lacking any mesenchymal markers.[3] In the VIdIr-<br>
model, on the other hand, we observed that single intraretina epithelial marker CK18, while lacking any mesenchymal markers.[3] In the VIdIr-/-<br>311 model, on the other hand, we observed that single intraretinal pigmented lesions a<br>312 expressed mesenchymal markers, possibly indicatin model, on the other hand, we observed that single intraretinal pigmented lesions also<br>312 expressed mesenchymal markers, possibly indicating the presence of different stages<br>313 of lesions. This was particularly the case f expressed mesenchymal markers, possibly indicating the presence of different stages<br>313 of lesions. This was particularly the case for lesions that were less dense, and thus<br>314 possibly less mature, indicating that some R 313 of lesions. This was particularly the case for lesions that were less dense, and thus<br>314 possibly less mature, indicating that some RPE-cells were still in a mesenchymal st<br>315 before undergoing MET and forming dense, possibly less mature, indicating that some RPE-cells were still in a mesenchymal state,<br>before undergoing MET and forming dense, mature plaques around the vessels. In<br>MacTel, on the other hand, intraretinal pigment plaques 315 before undergoing MET and forming dense, mature plaques around the vessels. In<br>316 MacTel, on the other hand, intraretinal pigment plaques usually develop within mont<br>317 and may form and progress over the course of se MacTel, on the other hand, intraretinal pigment plaques usually develop within months<br>and may form and progress over the course of several years, forming dense, organized<br>clusters of pigment around vessels.[3, 5] Thus, it 317 and may form and progress over the course of several years, forming dense, organized<br>318 clusters of pigment around vessels.[3, 5] Thus, it is conceivable that lesions, once<br>319 clinically detectable, are overall more clusters of pigment around vessels.[3, 5] Thus, it is conceivable that lesions, once<br>clinically detectable, are overall more mature, and RPE-cells within dense plaques<br>longer possess mesenchymal properties, possibly having clinically detectable, are overall more mature, and RPE-cells within dense plaques no<br>320 longer possess mesenchymal properties, possibly having transitioned back to an<br>321 epithelial state. Future studies are warranted to 320 longer possess mesenchymal properties, possibly having transitioned back to an<br>321 epithelial state. Future studies are warranted to further explore the proposed<br>322 mechanisms.<br>323 EMT of RPE-cells has been described 321 epithelial state. Future studies are warranted to further explore the proposed<br>322 mechanisms.<br>323 EMT of RPE-cells has been described in different ocular conditions[7] and va<br>324 inducers of EMT have previously been d

322 mechanisms.<br>323 EMT of RPE-c<br>324 inducers of EM<br>325 mice, we foun EMT of RPE-cells has been described in different ocular conditions[7] and various<br>324 inducers of EMT have previously been discussed.[7, 25, 29, 30] In the RPE of VIdli<br>325 mice, we found several known drivers of EMT to be inducers of EMT have previously been discussed.[7, 25, 29, 30] In the RPE of VIdIr-/-<br>mice, we found several known drivers of EMT to be enriched, with FGF2 and TNFa<br>being the most significant ones in our model. While these 325 mice, we found several known drivers of EMT to be enriched, with FGF2 and TNFa<br>326 being the most significant ones in our model. While these factors could be related to 326 being the most significant ones in our model. While these factors could be related to<br>
1326 being the most significant ones in our model. While these factors could be related to

15

general neovascularization events in the Vldlr-/- retina, it is important to note that their<br>inhibition actually reduced neovascularization and leakage, thus indicating a role in EM<br>rather than general neovascularization. inhibition actually reduced neovascularization and leakage, thus indicating a role in EMT<br>
rather than general neovascularization. Other known drivers of EMT and/or fibrosis<br>
have previously been identified in the VIdIr-/rather than general neovascularization. Other known drivers of EMT and/or fibrosis<br>330 have previously been identified in the VIdIr-/- model.[36, 37] Notably, EMT and TNFa<br>331 NFxB pathways were previously found to be amon have previously been identified in the Vldlr-/- model.[36, 37] Notably, EMT and TNFa/<br>331 NFKB pathways were previously found to be among the most significantly enriched<br>332 gene sets in RPE cells differentiated from induc NFκB pathways were previously found to be among the most significantly enriched<br>gene sets in RPE cells differentiated from induced pluripotent stem cells from MacT<br>donors.[38] This underlines the clinical relevance and ap gene sets in RPE cells differentiated from induced pluripotent stem cells from MacTel<br>donors.[38] This underlines the clinical relevance and applicability of our findings in the<br>VIdIr-/- model.<br>Inhibiting EMT in the VIdIrdonors.[38] This underlines the clinical relevance and applicability of our findings in the<br>334 VIdIr-/- model.<br>1335 Inhibiting EMT in the VIdIr-/- model resulted in increased neovascular growth and<br>1336 exudation, confirm 334 Vldlr-/- model.<br>335 Inhibiting EMT<br>336 exudation, con<br>337 clinically obser Inhibiting EMT in the Vldlr-/- model resulted in increased neovascular growth and<br>exudation, confirming the beneficial effect of perivascular pigment accumulation w<br>clinically observed in patients with MacTel. Pigment plaq exudation, confirming the beneficial effect of perivascular pigment accumulation we had<br>clinically observed in patients with MacTel. Pigment plaques, on the other hand, have<br>been shown to be associated with a focal loss in clinically observed in patients with MacTel. Pigment plaques, on the other hand, have<br>been shown to be associated with a focal loss in retinal sensitivity ("absolute scotomas<br>on fundus-controlled perimetry)[8, 39] and the been shown to be associated with a focal loss in retinal sensitivity ("absolute scotomas"<br>on fundus-controlled perimetry)[8, 39] and the pigment area with a decrease in visual<br>acuity in patients with MacTel[5], thus repres on fundus-controlled perimetry)[8, 39] and the pigment area with a decrease in visual<br>acuity in patients with MacTel[5], thus representing a mixed blessing.<br>Intravitreal VEGF inhibitors have been successfully used to treat acuity in patients with MacTel[5], thus representing a mixed blessing.<br>
1341 Intravitreal VEGF inhibitors have been successfully used to treat numer<br>
1342 diseases showing vascular involvement. In MacTel, VEGF inhibitors h 341 Intravitreal VEGF inhibitors have been successfully used to treat numerous retinal<br>342 diseases showing vascular involvement. In MacTel, VEGF inhibitors have been<br>343 effectively applied in eyes showing subretinal neov

diseases showing vascular involvement. In MacTel, VEGF inhibitors have been<br>
effectively applied in eyes showing subretinal neovascularization[40], while no fu<br>
improvement has been reached in non-neovascular eyes.[41] The effectively applied in eyes showing subretinal neovascularization[40], while no functional<br>
improvement has been reached in non-neovascular eyes.[41] The latter showed,<br>
however, a (temporary) decrease in fluorescein leaka improvement has been reached in non-neovascular eyes.[41] The latter showed,<br>
however, a (temporary) decrease in fluorescein leakage during treatment, followe<br>
an increase in leakage once treatment had been discontinued.[4 345 however, a (temporary) decrease in fluorescein leakage during treatment, followed by<br>346 an increase in leakage once treatment had been discontinued.[41] Notably, treated eye<br>347 developed excessive pigmentation and fi

346 an increase in leakage once treatment had been discontinued.[41] Notably, treated eyes<br>347 developed excessive pigmentation and fibrosis later on.[41, 42] In the VIdIr-/- model, we<br>348 found that perivascular pigment o

developed excessive pigmentation and fibrosis later on.[41, 42] In the VIdIr-/- model, we<br>
found that perivascular pigment only developed when vascular proliferation was present<br>
and pigment plaques only developed along pr

348 found that perivascular pigment only developed when vascular proliferation was present<br>349 and pigment plaques only developed along proliferating vessels. Taken together, this<br>16 349 and pigment plaques only developed along proliferating vessels. Taken together, this

might further indicate that interfering with the herein proposed natural "repair<br>351 mechanism" of the diseased retina/RPE, by suppressing either EMT or vascu<br>352 leakage/ intraretinal proliferation, may have detrimental e mechanism" of the diseased retina/RPE, by suppressing either EMT or vascular<br>1552 leakage/ intraretinal proliferation, may have detrimental effects and thus should b<br>1533 avoided in MacTel and related diseases.<br>154 **Conclu** leakage/ intraretinal proliferation, may have detrimental effects and thus should be<br>avoided in MacTel and related diseases.<br>**Conclusions:**<br>PEE LIP SUPPREY, We showed that perivascular pigment accumulation is associated wi

avoided in MacTel and related diseases.<br>354 **Conclusions**:<br>355 In summary, we showed that perivascular<br>355 In summary, we showed that perivascular 354 **Conclusions**:<br>355 In summary, w<br>356 decrease in va<br>357 retinal disease: In summary, we showed that perivascular pigment accumulation is associated with a<br>356 decrease in vascular leakage and stabilization of neovascular growth in proliferative<br>357 retinal diseases, such as MacTel, and respecti decrease in vascular leakage and stabilization of neovascular growth in proliferative<br>
retinal diseases, such as MacTel, and respective animal models. We revealed<br>
underlying mechanisms leading to perivascular pigment accu retinal diseases, such as MacTel, and respective animal models. We revealed<br>
underlying mechanisms leading to perivascular pigment accumulation, and dise<br>
beneficial effects, changing our current understanding of these cha underlying mechanisms leading to perivascular pigment accumulation, and discussed<br>
beneficial effects, changing our current understanding of these changes. Knowledge<br>
about pathophysiological mechanisms is crucial for unde beneficial effects, changing our current understanding of these changes. Knowledge<br>360 about pathophysiological mechanisms is crucial for understanding the disease course<br>361 and developing therapeutic interventions as wel 360 about pathophysiological mechanisms is crucial for understanding the disease course<br>361 and developing therapeutic interventions as well as choosing appropriate timepoints for<br>362 treatment. We conclude that interferin 361 and developing therapeutic interventions as well as choosing appropriate timepoints for<br>362 treatment. We conclude that interfering with this "natural repair mechanism" of the<br>363 diseased RPE may have detrimental effe 362 treatment. We conclude that interfering with this "natural repair mechanism" of the<br>363 diseased RPE may have detrimental effects on the course of the disease and shou<br>364 thus be avoided.<br>365 **Materials and Methods** diseased RPE may have detrimental effects on the course of the disease and should<br>164 thus be avoided.<br>**Materials and Methods**<br>266 **Participants** In a retrospective lengtudinal approach imaging data of affected

364 thus be avoided.<br>365 **Materials and Metalliers**<br>366 **Participants.** In a 365 **Materials and Methods**<br>366 **Participants.** In a retrosp<br>367 participants from twelve p<br>368 Macular Telangiectasia (I **Participants.** In a retrospective, longitudinal approach, imaging data of affected<br>participants from twelve participating sites of the multi-center Natural History Stu<br>Macular Telangiectasia (MacTel Study) were evaluated. participants from twelve participating sites of the multi-center Natural History Study of<br>368 Macular Telangiectasia (MacTel Study) were evaluated. Protocol details of this study<br>369 have been published previously.[43] The Macular Telangiectasia (MacTel Study) were evaluated. Protocol details of this study<br>have been published previously.[43] The diagnosis of MacTel type 2 was based on<br>characteristic morphologic findings on fundoscopy, OCT, f have been published previously.[43] The diagnosis of MacTel type 2 was based on<br>
characteristic morphologic findings on fundoscopy, OCT, fundus autofluorescence a<br>
fluorescein angiography[8], and was confirmed by the Moorf 370 characteristic morphologic findings on fundoscopy, OCT, fundus autofluorescence and<br>371 fluorescein angiography[8], and was confirmed by the Moorfields Eye Hospital Reading<br>1 371 fluorescein angiography[8], and was confirmed by the Moorfields Eye Hospital Reading<br>17<br>17

372 Centre, London, UK. Patients underwent annual study visits, and eyes were reviewed<br>373 over a minimum observational period of 24 months. The studies were approved by the<br>374 local ethics committees at each participatin over a minimum observational period of 24 months. The studies were approved by the<br>1374 local ethics committees at each participating study site and were in adherence with the<br>1375 Declaration of Helsinki. All participants local ethics committees at each participating study site and were in adherence with the<br>375 Declaration of Helsinki. All participants provided informed consent. Data were collected<br>376 at a minimum of two time points (at b Beclaration of Helsinki. All participants provided informed consent. Data were collected<br>at a minimum of two time points (at baseline and last available follow up visits), and<br>sites were selected based on the availability at a minimum of two time points (at baseline and last available follow up visits), and<br>sites were selected based on the availability of longitudinal imaging data, including c<br>fundus photography (CFP), Spectral Domain-OCT ( sites were selected based on the availability of longitudinal imaging data, including color<br>
fundus photography (CFP), Spectral Domain-OCT (SD-OCT; volume scans of 15° x 10°<br>
(high resolution mode, 97 scans) or 25° x 30° ( 378 fundus photography (CFP), Spectral Domain-OCT (SD-OCT; volume scans of 15° x 10°<br>379 (high resolution mode, 97 scans) or 25° x 30° (high speed mode, 61 scans); Spectralis,<br>380 Heidelberg Engineering, Heidelberg, German (high resolution mode, 97 scans) or 25° x 30° (high speed mode, 61 scans); Spectralis,<br>380 Heidelberg Engineering, Heidelberg, Germany), fundus autofluorescence (FA) and<br>381 fundus fluorescein angiography (FFA; 30°, center 380 Heidelberg Engineering, Heidelberg, Germany), fundus autofluorescence (FA) and<br>381 fundus fluorescein angiography (FFA; 30°, centered on the fovea, images taken at 3<br>382 seconds, 1, 5 and 10 minutes after fluorescein i 381 fundus fluorescein angiography (FFA; 30°, centered on the fovea, images taken at 30<br>382 seconds, 1, 5 and 10 minutes after fluorescein injection). In a small subset of<br>383 participants, OCT-angiography (OCT-A) data wer seconds, 1, 5 and 10 minutes after fluorescein injection). In a small subset of<br>participants, OCT-angiography (OCT-A) data were additionally available.<br>Inclusion criteria for this analysis were a confirmed diagnosis of Mac participants, OCT-angiography (OCT-A) data were additionally available.<br>1884 Inclusion criteria for this analysis were a confirmed diagnosis of MacTel, a<br>1885 including the examinations listed above and sufficient image qu Inclusion criteria for this analysis were a confirmed diagnosis of MacTel, a full data set<br>including the examinations listed above and sufficient image quality. As pigmentary<br>changes have been shown to only develop in eyes including the examinations listed above and sufficient image quality. As pigmentary<br>386 changes have been shown to only develop in eyes showing disruptions of outer retir<br>387 layers[44], and to ensure equal baseline condit changes have been shown to only develop in eyes showing disruptions of outer retinal<br>387 layers[44], and to ensure equal baseline conditions among both groups, only eyes with<br>388 intermediate disease stages were included. layers[44], and to ensure equal baseline conditions among both groups, only eyes with<br>intermediate disease stages were included. The latter was defined as visible disruption<br>of the ellipsoid zone (EZ)/ photoreceptor layer intermediate disease stages were included. The latter was defined as visible disruption<br>of the ellipsoid zone (EZ)/ photoreceptor layer on OCT, and disease stages 2-3<br>according to Gass and Blodi.[13] Eyes showing pigment p 389 of the ellipsoid zone (EZ)/ photoreceptor layer on OCT, and disease stages 2-3<br>390 according to Gass and Blodi.[13] Eyes showing pigment plaques and/ or subreti<br>391 sub-RPE neovascular membranes (stages 4 and 5 accordi according to Gass and Blodi.[13] Eyes showing pigment plaques and/ or subretinal/<br>sub-RPE neovascular membranes (stages 4 and 5 according to Gass and Blodi) at<br>baseline were excluded. Further exclusion criteria were the pr sub-RPE neovascular membranes (stages 4 and 5 according to Gass and Blodi) at<br>baseline were excluded. Further exclusion criteria were the presence of potentially<br>confounding retinal diseases including central serous chorio 392 baseline were excluded. Further exclusion criteria were the presence of potentially<br>
confounding retinal diseases including central serous chorioretinopathy, age-related<br>
confounding retinal diseases including central 393 confounding retinal diseases including central serous chorioretinopathy, age-related

18

- 
- 
- macular degeneration or diabetic retinopathy, and previous therapies including VEGF-<br>inhibitors, vitreo-retinal surgery, photodynamic therapy or central laser treatment.<br>Eyes were retrospectively divided into two groups, o inhibitors, vitreo-retinal surgery, photodynamic therapy or central laser treatment.<br>396 Eyes were retrospectively divided into two groups, one group showing a *de novo*<br>397 formation of pigment plaques at last follow up, Eyes were retrospectively divided into two groups, one group showing a *de novo*<br>formation of pigment plaques at last follow up, and one group without any pigmer<br>changes, and outcome parameters were compared between both g
- 
- 
- 397 formation of pigment plaques at last follow up, and one group without any pigmentary<br>398 changes, and outcome parameters were compared between both groups.<br>399 Outcome parameters included changes in leakage on FFA (dec changes, and outcome parameters were compared between both groups.<br>399 Cutcome parameters included changes in leakage on FFA (decreased, inc<br>300 stable leakage within subfields 1-5 of the ETDRS grid) and a *de novo* deve<br>3 399 Outcome parameters included changes in leakage on FFA (decreased, increased, or<br>300 stable leakage within subfields 1-5 of the ETDRS grid) and a *de novo* development of<br>301 exudative subretinal neovascular membranes a
- 400 stable leakage within subfields 1-5 of the ETDRS grid) and a *de novo* development of<br>
401 exudative subretinal neovascular membranes as observed on CFP, OCT, FFA, and<br>
402 OCT-A (if available).<br> **Image grading and def** exudative subretinal neovascular membranes as observed on CFP, OCT, FFA, and<br>402 OCT-A (if available).<br>**Image grading and definitions.**<br>404 **Pigment plaques** CEP and EA images were analyzed for the presence and position
- 

- 402 OCT-A (if available).<br>403 **Image grading and (404 Pigment plaques. C**<br>405 **Digment plaques at b Image grading and definitions.<br>
404 Pigment plaques. CFP and FA in<br>
405 pigment plaques at baseline and l<br>
406 Leakage on FFA On FFA vesse Pigment plaques.** CFP and FA images were analyzed for the presence and position of<br>pigment plaques at baseline and last follow up.<br>**Leakage on FFA.** On FFA, vessels were graded for an (1) increase, (2) decrease, or<br>(3) no
- pigment plaques at baseline and last follow up.<br>406 **Leakage on FFA.** On FFA, vessels were grade<br>407 (3) no visible changes in fluorescein leakage at<br>408 Images were evaluated and compared at differe
- 
- **Leakage on FFA.** On FFA, vessels were graded for an (1) increase, (2) decrease, or<br>
(3) no visible changes in fluorescein leakage at last follow up compared to baseline.<br>
Images were evaluated and compared at different ti (3) no visible changes in fluorescein leakage at last follow up compared to baseline.<br>
Images were evaluated and compared at different time points (at 30 seconds, 1 minu<br>
and 10 minutes after fluorescein injection) and wit
- Images were evaluated and compared at different time points (at 30 seconds, 1 minute,<br>and 10 minutes after fluorescein injection) and within subfields 1-5 of the ETDRS grid.<br>**Neovascularization and exudation.** Previously d
- 
- 
- and 10 minutes after fluorescein injection) and within subfields 1-5 of the ETDRS grid.<br> **Neovascularization and exudation.** Previously described criteria were applied to<br>
identify neovascular membranes on OCT, FFA, CFP, a Atla **Neovascularization and exudation.** Previously described criteria were applied to<br>
identify neovascular membranes on OCT, FFA, CFP, and OCT-A images (if<br>
available).[16, 44] Neovascular exudation was defined as focal 411 identify neovascular membranes on OCT, FFA, CFP, and OCT-A images (if<br>412 available).[16, 44] Neovascular exudation was defined as focal retinal thicker<br>413 or intraretinal fluid, and/or hemorrhages as observed on OCT
- available).[16, 44] Neovascular exudation was defined as focal retinal thickening, sub-<br>or intraretinal fluid, and/or hemorrhages as observed on OCT and/ or CFP in<br>neovascular eyes. 413 or intraretinal fluid, and/or hemorrhages as observed on OCT and/ or CFP in<br>144 neovascular eyes.
- 414 neovascular eyes.



effective in this model.[21, 36] Retinas were evaluated at P28 using<br>
immunofluorescence imaging. At this timepoint, the normal RPE mor<br>
immunofluorescence imaging. At this timepoint, the normal RPE more immunofluorescence imaging. At this timepoint, the normal RPE monolayer is disrupted,<br>
20<br>
20

and clumps of RPE cells accumulate along neovascular tufts in the subretinal space of<br>438 VIdIr-/- mice.[19, 21]<br>**Dextran angiography.** For analyzing vascular leakage, Fluorescein isothiocyanate—<br>440 dextran (FITC; 40,000 438 VldIr-/- mice.[19, 21]<br>439 **Dextran angiograph<br>440 dextran (FITC**; 40,00<br>441 deeply anesthetized **Dextran angiography.** For analyzing vascular leakage, Fluorescein isothiocyanate—<br>dextran (FITC; 40,000 MW; Sigma-Aldrich) was perfused through the left ventricle of<br>deeply anesthetized VIdIr-/- animals using 150µl of a 5

dextran (FITC; 40,000 MW; Sigma-Aldrich) was perfused through the left ventricle of<br>deeply anesthetized VIdIr-/- animals using 150µI of a 50mg/mI solution in PBS.<br>**Immunofluorescence**. Retinas and RPE/choroid complexes wer deeply anesthetized Vldlr-/- animals using 150µl of a 50mg/ml solution in PBS.<br> **Immunofluorescence**. Retinas and RPE/choroid complexes were dissected ar<br>
prepared for whole mounts or sectioning. For preparation of retinal **Immunofluorescence**. Retinas and RPE/choroid complexes were dissected and<br>prepared for whole mounts or sectioning. For preparation of retinal cross-sections<br>isolated eyes were fixed in 4% paraformaldehyde (PFA) for 4 hour prepared for whole mounts or sectioning. For preparation of retinal cross-sections,<br>isolated eyes were fixed in 4% paraformaldehyde (PFA) for 4 hours, placed in 15%<br>sucrose overnight at 4°C, followed by 30% sucrose for 2 h isolated eyes were fixed in 4% paraformaldehyde (PFA) for 4 hours, placed in 15%<br>sucrose overnight at 4°C, followed by 30% sucrose for 2 hours, and embedded in<br>Tissue-Tek OCT compound (Sakura Finetek) for subsequent cryose sucrose overnight at 4°C, followed by 30% sucrose for 2 hours, and embedded in<br>446 Tissue-Tek OCT compound (Sakura Finetek) for subsequent cryosectioning. For<br>447 preparation of whole mounts, eyes were fixed in 4% PFA for Tissue-Tek OCT compound (Sakura Finetek) for subsequent cryosectioning. For<br>preparation of whole mounts, eyes were fixed in 4% PFA for one hour, and<br>retina/RPE/choroid complexes were dissected and laid flat. Whole-mount<br>re preparation of whole mounts, eyes were fixed in 4% PFA for one hour, and<br>
448 retina/RPE/choroid complexes were dissected and laid flat. Whole-mount<br>
449 retina/RPE/choroid complexes or cryosections were incubated in block retina/RPE/choroid complexes were dissected and laid flat. Whole-mount<br>retina/RPE/choroid complexes or cryosections were incubated in blocking<br>fetal bovine serum and 0.1% Triton X-100 in phosphate-buffered saline [P<br>for 2 retina/RPE/choroid complexes or cryosections were incubated in blocking buffer (10%<br>fetal bovine serum and 0.1% Triton X-100 in phosphate-buffered saline [PBS]) at 4°C<br>for 2 hours, followed by an incubation with primary an fetal bovine serum and 0.1% Triton X-100 in phosphate-buffered saline [PBS]) at 4°C<br>for 2 hours, followed by an incubation with primary antibodies in blocking buffer at 4°C<br>overnight. Specimens were then washed with PBS an for 2 hours, followed by an incubation with primary antibodies in blocking buffer at 4°C<br>
overnight. Specimens were then washed with PBS and incubated with Alexa Fluor-<br>
conjugated secondary antibodies (Thermo Fisher) for overnight. Specimens were then washed with PBS and incubated with Alexa Fluor–<br>conjugated secondary antibodies (Thermo Fisher) for 2 hours. Nuclei were stained<br>using DAPI (Vector Laboratories). Specimen were mounted in Vec conjugated secondary antibodies (Thermo Fisher) for 2 hours. Nuclei were stained<br>using DAPI (Vector Laboratories). Specimen were mounted in Vectashield Plus Ant<br>Mounting Medium (Vectorlabs). Primary antibodies against ZO-1 using DAPI (Vector Laboratories). Specimen were mounted in Vectashield Plus Antifade<br>
Mounting Medium (Vectorlabs). Primary antibodies against ZO-1 (40-2200, Thermo<br>
Fisher), RPE-65 (PA5-110315, Thermo Fisher), alpha-smoot Mounting Medium (Vectorlabs). Primary antibodies against ZO-1 (40-2200, Thermo<br>456 Fisher), RPE-65 (PA5-110315, Thermo Fisher), alpha-smooth muscle actin (ab1249<br>457 Abcam), IBA1 (MA5-27726, Thermo Fisher) and Cytokeratin 456 Fisher), RPE-65 (PA5-110315, Thermo Fisher), alpha-smooth muscle actin (ab124964,<br>Abcam), IBA1 (MA5-27726, Thermo Fisher) and Cytokeratin 18 (10830-1-AP,<br>Proteintech) were used. Endothelial cells were labeled using Flu 457 Abcam), IBA1 (MA5-27726, Thermo Fisher) and Cytokeratin 18 (10830-1-AP,<br>
458 Proteintech) were used. Endothelial cells were labeled using Fluorescent-conji<br>
isolectin Griffonia Simplicifolia IB-4 (GS-Lectin) (I21412, T 458 Proteintech) were used. Endothelial cells were labeled using Fluorescent-conjugated<br>isolectin Griffonia Simplicifolia IB-4 (GS-Lectin) (I21412, Thermo Fisher). Images were<br>isolectin Griffonia Simplicifolia IB-4 (GS-Lec 459 isolectin Griffonia Simplicifolia IB-4 (GS-Lectin) (I21412, Thermo Fisher). Images were

captured with a confocal laser scanning microscope (LSM 710, Zeiss) and processed<br>with the ZEN 2010 software (Zeiss). The NIH ImageJ software was used for quantifyin<br>dextran-leakage (number of pixels positive for dextran), with the ZEN 2010 software (Zeiss). The NIH ImageJ software was used for quantifying<br>dextran-leakage (number of pixels positive for dextran), pigment accumulation (number<br>of pixels positive for pigment) and neovascular tuf dextran-leakage (number of pixels positive for dextran), pigment accumulation (number<br>of pixels positive for pigment) and neovascular tufts (total numbers of visible tufts per<br>eye).<br>**Gene expression analyses.** For quantita

of pixels positive for pigment) and neovascular tufts (total numbers of visible tufts per<br>eye).<br>**Gene expression analyses.** For quantitative polymerase chain reaction (qPCR),<br>retinas and RPE/choroid complexes were isolated 464 eye).<br>465 **Gene**<br>466 retina<br>467 perfor Gene expression analyses. For quantitative polymerase chain reaction (qPCR),<br>tetinas and RPE/choroid complexes were isolated in 500µl Trizol. RNA isolation w<br>performed using a RNeasy Plus Micro Kit (Qiagen) following the m retinas and RPE/choroid complexes were isolated in 500μl Trizol. RNA isolation was<br>performed using a RNeasy Plus Micro Kit (Qiagen) following the manufacturer's<br>instructions. 400ng RNA was used for real time-qPCR using th performed using a RNeasy Plus Micro Kit (Qiagen) following the manufacturer's<br>
instructions. 400ng RNA was used for real time-qPCR using the High-capacity cl<br>
Reverse transcriptase kit (Thermo Fisher). SYBR Green–based (Th instructions. 400ng RNA was used for real time-qPCR using the High-capacity cDNA<br>Reverse transcriptase kit (Thermo Fisher). SYBR Green–based (Thermo Fisher) real-<br>time quantitative PCR was performed on a QuantStudio 5 (The Reverse transcriptase kit (Thermo Fisher). SYBR Green–based (Thermo Fisher) real-<br>
470 time quantitative PCR was performed on a QuantStudio 5 (Thermo Fisher) to analyze<br>
471 mRNA expression levels of various gene products. time quantitative PCR was performed on a QuantStudio 5 (Thermo Fisher) to analyze<br>mRNA expression levels of various gene products. Expression levels were normalized<br>to Cyclophilin A. Sequences of primers used are listed in mRNA expression levels of various gene products. Expression levels were normalized<br>to Cyclophilin A. Sequences of primers used are listed in supplementary table 1. Data<br>were analyzed using the QuantStudio Design and Analys to Cyclophilin A. Sequences of primers used are listed in supplementary table 1. Data<br>were analyzed using the QuantStudio Design and Analysis Software 2.6.0 (Thermo<br>Fisher).<br>**Statistical analysis.** Statistical analyses wer were analyzed using the QuantStudio Design and Analysis Software 2.6.0 (Thermo<br>174 Fisher).<br>**Statistical analysis.** Statistical analyses were performed using GraphPad Prism,<br>176 version 10.1.0 (GraphPad Software, San Die

474 Fisher).<br>475 **Statistic**<br>476 version<br>477 describe **Statistical analysis.** Statistical analyses were performed using GraphPad Prism,<br>version 10.1.0 (GraphPad Software, San Diego, CA, USA). Continuous variables \<br>described by using the mean ± standard deviation (SD), median version 10.1.0 (GraphPad Software, San Diego, CA, USA). Continuous variables were<br>described by using the mean ± standard deviation (SD), median and interquartile range<br>[IQR] and/ or ranges. Categorical variables were descr described by using the mean ± standard deviation (SD), median and interquartile range<br>[IQR] and/ or ranges. Categorical variables were described in terms of frequency.<br>Unpaired t-test with Welch's correction was applied fo [IQR] and/ or ranges. Categorical variables were described in terms of frequency.<br>
Unpaired t-test with Welch's correction was applied for comparing parameters bet<br>
two groups in normally distributed samples. Mann–Whitney Unpaired t-test with Welch's correction was applied for comparing parameters between<br>two groups in normally distributed samples. Mann–Whitney test was used to compare<br>parameters between two groups in non-normally distribut two groups in normally distributed samples. Mann–Whitney test was used to compare<br>parameters between two groups in non-normally distributed samples. Kruskal-Wallis<br>test with Dunn's correction for multiple comparisons was u 481 parameters between two groups in non-normally distributed samples. Kruskal-Wallis<br>182 test with Dunn's correction for multiple comparisons was used to compare data betwe<br>182 test with Dunn's correction for multiple comparisons was used to compare data between<br>
22<br>
22

- 
- multiple groups. Fisher's exact test was applied to analyze contingency tables with<br>484 small sample sizes. Pearson correlation coefficient was calculated to determine line<br>485 correlation between two parameters. Statistic
- 
- small sample sizes. Pearson correlation coefficient was calculated to determine linear<br>correlation between two parameters. Statistical tests applied for each experiment are<br>detailed in the figure and table legends. A p-val correlation between two parameters. Statistical tests applied for each experiment are<br>detailed in the figure and table legends. A p-value <0.05 was accepted as statistically<br>significant.<br>**References**
- 

- detailed in the figure and table legends. A p-value <0.05 was accepted as statistically<br>significant.<br>**References**<br>1. George SM, Lu F, Rao M, Leach LL, Gross JM: The retinal pigment epithelium: Development, 487 significant.<br>488 **Reference:**<br>489 1. Georg<br>490 injury<br>491 *Retin* **488 References**<br> **489 1.** George<br> **490** injury r<br> **491** *Retin E*<br> **492 2.** Li ZY, P<br> **493** *Ophtha*<br> **493** *Ophtha*
- 490 injury responses, and regenerative potential in mammalian and non-mammalian systems. P<br>
491 Retin Eye Res 2021, 85:100969.<br>
492 2. Li ZY, Possin DE, Milam AH: Histopathology of bone spicule pigmentation in retinitis pi Figure 1996 in the Res 2021, 85:100969.<br>
491 Retin Eye Res 2021, 85:100969.<br>
492 Li ZY, Possin DE, Milam AH: Histopathology of bone spicule pigmentation in retinitis pigmentosa<br>
493 Ophthalmology 1995, 102(5):805-816.<br>
494
- 
- 492 2. Li ZY, Possin DE, Milam AH: Histopae<br>493 0phthalmology 1995, 102(5):80<br>494 3. Yasvoina M, Yang Q, Woods SM.<br>495 cells in retinal degenerative dise<br>496 4. Miura M, Makita S, Sugiyama S,<br>497 Goto H: Evaluation of intr 493 Ophthalmology 1995, 102(5):805-816.<br>
494 3. Yasvoina M, Yang Q, Woods SM, Heeren T, Comer GM, C AE, Fruttiger M: Intraretinal pigmented<br>
495 cells in retinal degenerative disease. *Br J Ophthalmol* 2023, 107(11):1736-1 Example 1995<br>
494 3. Yasvoina M, Yang Q, Woods SM, Heere<br>
495 cells in retinal degenerative disease. *Br*<br>
496 4. Miura M, Makita S, Sugiyama S, Hong Y<br>
497 Goto H: Evaluation of intraretinal migra<br>
498 macular degeneratio
- 495<br>
4. Miura M, Makita S, Sugiyama S, Hong YJ, Yasuno Y, Elsner AE, Tamiya S, Tsukahara R, Iwasaki T,<br>
497 Goto H: Evaluation of intraretinal migration of retinal pigment epithelial cells in age-related<br>
498 macular degen 496 4. Miura M, Makita S, Sugiyama S, Hong YJ, Yasuno Y, Elsner AE, Tamiya S, Tsukaha<br>497 Goto H: Evaluation of intraretinal migration of retinal pigment epithelial cells in<br>498 macular degeneration using polarimetric imag Goto H: Evaluation of intraretinal migration of retinal pigment epithelial cells in age-related<br>
498 macular degeneration using polarimetric imaging. *Sci Rep* 2017, 7(1):3150.<br>
499 5. Leung I, Sallo FB, Bonelli R, Clemons 498 macular degeneration using polarimetric imaging. Sci Rep 2017, 7(1):3150.<br>499 5. Leung I, Sallo FB, Bonelli R, Clemons TE, Pauleikhoff D, Chew EY, Bird AC, Peto T, MacTel Studen<br>500 Characteristics of Pigmented Lesions 498 5. Leung I, Sallo FB, Bonelli R, Clemons TE, Pauleikhoff D, Chew EY, Bird AC, Pe<br>
200 Characteristics of Pigmented Lesions in Type 2 Idiopathic Macular Telangies<br>
38 Suppl 1:S43-S50.<br>
502 6. Tamiya S, Liu L, Kaplan HJ:
- 499 5. Characteristics of Pigmented Lesions in Type 2 Idiopathic Macular Telangiectasia. *Retina* 2018,<br>
501 58 Suppl 1:543-550.<br>
502 6. Tamiya S, Liu L, Kaplan HJ: Epithelial-mesenchymal transition and proliferation of re
- 501 Characteristics of Pigmented Ecsions in Type 2 Idiopathic Macdial Telangiectasia. Nethia 2016,<br>
501 38 Suppl 1:S43-S50.<br>
502 6. Tamiya S, Liu L, Kaplan HJ: Epithelial-mesenchymal transition and proliferation of retinal 502 6. Tamiya S, Liu L, Kapl.<br>503 pigment epithelial ce<br>504 51(5):2755-2763.<br>505 7. Zhou M, Geathers JS<br>506 Mesenchymal Transi<br>507 8:501.<br>508 8. Charbel Issa P, Gillie: 503 bigment epithelial cells initiated upon loss of cell-cell contact. *Invest Ophthalmol Vis Sci*<br>
504 51(5):2755-2763.<br>
505 7. Zhou M, Geathers JS, Grillo SL, Weber SR, Wang W, Zhao Y, Sundstrom JM: Role of Epithe<br>
506 M Figment epithelial cells initiated upon loss of cell-cell contact. *Invest Ophthalmor VIS 3CI 2010*,<br>
504 51(5):2755-2763.<br>
7. Zhou M, Geathers JS, Grillo SL, Weber SR, Wang W, Zhao Y, Sundstrom JM: Role of Epithelial-<br>
Me 505 7. Zhou M, Geathers<br>506 Mesenchymal Tra<br>507 8:501.<br>508 8. Charbel Issa P, Gil<br>509 telangiectasia type<br>510 9. Tzaridis S, Heeren<br>511 Herrmann, Philipp
- 
- 512 *press*) 2019. Mesenchymal Transition in Rethial Pigment Epithelium Dysiumetion. Front Cell Dev Biol 2020,<br>
8.501.<br>
8. Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, Holz FG, Scholl HP: Macular<br>
telangiectasia type 2. 508 8. Charbe<br>
509 8. Charbe<br>
510 9. Tzaridi:<br>
511 Herrma<br>
512 *press*)<br>
513 10. Tzaridi:<br>
514 Quanti 108 108 11 10. Charbel Issa P, Herren Islam Picture McCharbel Issa Peter, Tiebo F.C., Mai, Clarissa, Thiele, Sarah, Holz, Frank G, Charbel Issa, Peter, Herrmann, Philipp: Right-angled vessels in macular telangiectasia type 510 9. Taridis S, Heeren, Tjebo F.C., Mai, Clarissa, Thiele, Sarah, Herrmann, Philipp: Right-angled vessels in macular telang<br>512 press) 2019.<br>513 10. Tzaridis S, Wintergerst MWM, Mai C, Heeren TFC, Holz FC<br>514 Quantificat
- Fiangled vessels in macular telangiectasia type 2. *Br J Ophthalmol (in*<br>
Fiangles 2. Travidis S, Wintergerst MWM, Mai C, Heeren TFC, Holz FG, Charbel Issa P, Herrmann P:<br>
10. Tzaridis S, Wintergerst MWM, Mai C, Heeren TFC
- Fremmann, Philipp: Right-angled vessels in macular telangiectasia type 2. Br J Ophthalmol (in<br>
Fass) 2019.<br>
10. Tzaridis S, Wintergerst MWM, Mai C, Heeren TFC, Holz FG, Charbel Issa P, Herrmann P:<br>
1514 Quantification of R Example 10. Transferences<br>
513 10. Transfering S. W.<br>
515 11. Breazzano M<br>
517 11. Breazzano M<br>
517 11. Breazzano M<br>
518 98. I2. Breazzano M 514 Quantification of Retinal and Choriocapillaris Perfusion in Different Stages of Macular<br>515 Telangiectasia Type 2. *Invest Ophthalmol Vis Sci* 2019, 60(10):3556-3562.<br>516 11. Breazzano MP, Yannuzzi LA, Spaide RF: Chara 515 Telangiectasia Type 2. *Invest Ophthalmol Vis Sci* 2019, 60(10):3556-3562.<br>516 11. Breazzano MP, Yannuzzi LA, Spaide RF: Characterizing Retinal-Choroidal Anastomosis in Telangiectasia Type 2 with Optical Coherence Tomo Felangiectasia Type 2. *Invest Ophthalmol Vis Sci* 2019, 80(10):3556-3562.<br>
516 11. Breazzano MP, Yannuzzi LA, Spaide RF: Characterizing Retinal-Choroidal A<br>
517 98.<br>
520 12. Breazzano MP, Yannuzzi LA, Spaide RF: Genesis o Telangiectasia Type 2 with Optical Coherence Tomography Angiography. Retina 2020, 40(1):92-<br>
518 12. Breazzano MP, Yannuzzi LA, Spaide RF: Genesis of Retinal-Choroidal Anastomosis in Macular<br>
520 13. Gass JD, Blodi BA: Idi
- 
- Felangiectasia Type 2 with Optical Coherence Tomography Anglography. Retina 2020, 40(1):32-<br>
98.<br>
519 12. Breazzano MP, Yannuzzi LA, Spaide RF: Genesis of Retinal-Choroidal Anastomosis in Macular<br>
Telangiectasia Type 2: A 518 98. 520 Telangiectasia Type 2: A Longitudinal Analysis. *Retina* 2020.<br>521 13. Gass JD, Blodi BA: Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. *Ophthalmology* 1993, 100(10):153 Telangiectasia Type 2: A Longitudinal Analysis. Retina 2020.<br>521 13. Gass JD, Blodi BA: Idiopathic juxtafoveolar retinal telangiecta<br>522 follow-up study. *Ophthalmology* 1993, 100(10):1536-1546. 522 follow-up study.  $Opthalmology$  1993, 100(10):1536-1546. 522 follow-up study. Ophthalmology 1993, 100(10):1536-1546.

524 idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol 2002, 120(3):320-324.<br>525 15. Davidorf FH, Pressman MD, Chambers RB: Juxtafoveal telangiectasis-a name change? Retind<br>526 2004, 24(3):474-478.<br>527 16. Heeren TFC 15. Idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol 2002, 120(3):320-324.<br>
15. Idiopathic film, Pressman MD, Chambers RB: Juxtafoveal telangiectasis-a name cha<br>
16. Idiopathic Film, Pressman MD, Chambers RB: Juxta 525 15. Bavidorf FH, Fressman MD, Chambers RD. Jaktafovear changiectasis-a name change? Retina<br>526 2004, 24(3):474-478.<br>527 16. Heeren TFC, Chew EY, Clemons T, Fruttiger M, Balaskas K, Schwartz R, Egan CA, Charbel Issa F<br>5 527 16. Heeren TFC, Chew EY<br>
528 MacTel Study G: MacTel<br>
530 17. Mueller S, Gunneman<br>
531 phenotypical variation<br>
532 2. *Br J Ophthalmol* 20<br>
533 18. Heckenlively JR, Hawe MacTel Study G: Macular Telangiectasia Type 2: Visual Acuity, Disease End Stage, and the<br>
S29 MacTel Area: MacTel Project Report Number 8. Ophthalmology 2020.<br>
17. Mueller S, Gunnemann F, Rothaus K, Book M, Faatz H, Bird A MacTel Area: MacTel Project Report Number 8. Ophthalmology 2020.<br>
17. Mueller S, Gunnemann F, Rothaus K, Book M, Faatz H, Bird A, Pauleikhoff D: Incidence and<br>
17. Mueller S, Gunnemann F, Rothaus K, Book M, Faatz H, Bird A MacTel Area: MacTel Toject Report Number 8. Ophthalmology 2020.<br>
17. Mueller S, Gunnemann F, Rothaus K, Book M, Faatz H, Bird A, Pauleikh<br>
phenotypical variation of outer retina-associated hyperreflectivity in m<br>
2. *Br J* phenotypical variation of outer retina-associated hyperreflectivity in macular telangiectasia<br>
532 2. *Br J Ophthalmol* 2021, 105(4):573-576.<br>
533 18. Heckenlively JR, Hawes NL, Friedlander M, Nusinowitz S, Hurd R, Davisso 2. Br J Ophthalmol 2021, 105(4):573-576.<br>
533 18. Heckenlively JR, Hawes NL, Friedlander M, Nusinowitz S, Hurd R, Davisson M, Chang B: Mouse<br>
534 model of subretinal neovascularization with choroidal anastomosis. *Retina* 2. Br J Ophthalmol 2021, 105(4):373-576.<br>
533 18. Heckenlively JR, Hawes NL, Friedlander M<br>
535 19. Hu W, Jiang A, Liang J, Meng H, Chang B, C<br>
536 evolution of subretinal neovascularization<br>
537 proliferation. *Invest Oph* model of subretinal neovascularization with choroidal anastomosis. *Retina* 2003, 23(4):518-52<br>535 19. Hu W, Jiang A, Liang J, Meng H, Chang B, Gao H, Qiao X: Expression of VLDLR in the retina and<br>636 evolution of subretin 19. Hu W, Jiang A, Liang J, Meng H, Chang B, Gao H, Qiao X: Expression of VLDLR in the retina and<br>
536 evolution of subretinal neovascularization in the knockout mouse model's retinal angiomatous<br>
proliferation. *Invest Op* evolution of subretinal neovascularization in the knockout mouse model's retinal angiomatous<br>
starp are proliferation. *Invest Ophthalmol Vis Sci* 2008, 49(1):407-415.<br>
20. Augustin M, Fialova S, Himmel T, Glosmann M, Leng evolution of subretinal neovascularization in the knockout mouse model's retinal angiomatous<br>
537 proliferation. *Invest Ophthalmol Vis Sci* 2008, 49(1):407-415.<br>
538 20. Augustin M, Fialova S, Himmel T, Glosmann M, Lenghe S38 20. Augustin M, Fialova S, Himmel T, Glosmann M, Lengheimer T<br>539 M, Hitzenberger CK, Baumann B: Multi-Functional OCT Enablement<br>540 Changes in a VLDLR Knockout Mouse Model. *PLoS One* 2016,<br>541 21. Dorrell MI, Aguilar M, Hitzenberger CK, Baumann B: Multi-Functional OCT Enables Longitudinal Study of Retinal<br>
Changes in a VLDLR Knockout Mouse Model. *PLoS One* 2016, 11(10):e0164419.<br>
21. Dorrell MI, Aguilar E, Jacobson R, Yanes O, Gariano Changes in a VLDLR Knockout Mouse Model. *PLoS One* 2016, 11(10):e0164419.<br>
21. Correll MI, Aguilar E, Jacobson R, Yanes O, Gariano R, Heckenlively J, Banin E, Ramirez GA, Ga<br>
22. M, Bird A et al: Antioxidant or neurotroph Sachington a VLDLR Knockout Mouse Mouch. Plos One 2010, 11(10):e0104415.<br>
541 21. Dorrell MI, Aguilar E, Jacobson R, Yanes O, Gariano R, Heckenlively J, Banin E, Ra<br>
542 M, Bird A et al. Antioxidant or neurotrophic factor 21. Dorrell MI, Aguilar E, Jacobson R, Yanes O, Gariano R, Heckenlively J, Banin E, Ramirez GA, Gasmi<br>
542 M, Bird A *et al*: Antioxidant or neurotrophic factor treatment preserves function in a mouse<br>
543 model of neovasc M, Bird A et al: Antioxidant or neurotrophic factor treatment preserves function in a model<br>
stade in the model of neovascularization-associated oxidative stress. *J Clin Invest* 2009, 119(3):611-623.<br>
Stade 12. Sun Y, Lin model of neovascularization-associated oxidative stress. J clim invest 2009, 119(3):011-023.<br>
544 22. Sun Y, Lin Z, Liu CH, Gong Y, Liegl R, Fredrick TW, Meng SS, Burnim SB, Wang Z, Akula JD et a<br>
545 Inflammatory signals 544 22. Sun Y, Lin Z, Lid CH, Gong Y, Liegi N, Tredrick TW, Weng 35, Burnin 5b, Wang Z, Akula 3D et di.<br>545 Inflammatory signals from photoreceptor modulate pathological retinal angiogenesis via c-Fos<br>546 Exp Med 2017, 214 Exp Med 2017, 214(6):1753-1767.<br>
Exp Med 2017, 214(6):1753-1767.<br>
Exp Med 2017, 214(6):1753-1767.<br>
Exp Med 2017, 214(6):1753-1767.<br>
Retinas of Very Low-Density Lipoprotein Receptor Knockout Mice: An Animal Model of Retinal Exp Med 2017, 214(0):1753-1767.<br>
547 23. Li C, Huang Z, Kingsley R, Zhou X, L<br>
548 Retinas of Very Low-Density Lipopi<br>
550 24. Chen HC, Zhu YT, Chen SY, Tseng S<br>
551 with proliferation in ARPE-19 cells<br>
552 687.<br>
25. Matsu Retinas of Very Low-Density Lipoprotein Receptor Knockout Mice: An Animal Model of Re<br>
549 Angiomatous Proliferation. Archives of Ophthalmology 2007, 125(6):795-803.<br>
24. Chen HC, Zhu YT, Chen SY, Tseng SC: Wnt signaling i Angiomatous Proliferation. Archives of Ophthalmology 2007, 125(6):795-803.<br>
24. Chen HC, Zhu YT, Chen SY, Tseng SC: Wnt signaling induces epithelial-mesenchymal transition<br>
with proliferation in ARPE-19 cells upon loss of 24. Chen HC, Zhu YT, Chen SY, Tseng SC: Wnt signaling induces epithelial-mesench<br>
550 24. Chen HC, Zhu YT, Chen SY, Tseng SC: Wnt signaling induces epithelial-mesench<br>
551 with proliferation in ARPE-19 cells upon loss of c with proliferation in ARPE-19 cells upon loss of contact inhibition. *Lab Invest* 2012, 92(5):676-<br>552 687.<br>25. Matsuda Y, Nonaka Y, Futakawa S, Imai H, Akita K, Nishihata T, Fujiwara M, Ali Y, Bhisitkul RB,<br>554 Nakamura Y with prolleration in ARPE-19 cells upon loss of contact inhibition. *Lub livest 2012*, 92(9):076-<br>
552 087.<br>
Matsuda Y, Nonaka Y, Futakawa S, Imai H, Akita K, Nishihata T, Fujiwara M, Ali Y, Bhisitkul RB,<br>
Nakamura Y: Anti 553 25. Mats<br>554 Naka<br>555 26. Schu<br>556 26. Schu<br>557 27. Wan<sub>i</sub><br>558 celln<br>559 Akt/r Makamura Y: Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factory (1955)<br>
1955 26. Matter in Animal Models of Retinal Disease. *Mol Ther Nucleic Acids* 2019, 17:819-828.<br>
1956 26. Schultz GS, G 2 Aptamer in Animal Models of Retinal Disease. *Mol Ther Nucleic Acids* 2019, 17:819-828.<br>
556 26. Schultz GS, Grant MB: Neovascular growth factors. *Eye (Lond)* 1991, 5 (Pt 2):170-180.<br>
27. Wang CH, Cao GF, Jiang Q, Yao J 2 Aptamer in Animal Models of Nethial Disease. Mor Ther Nucleic Acids 2019, 17:819-828.<br>
26. Schultz GS, Grant MB: Neovascular growth factors. Eye (Lond) 1991, 5 (Pt 2):170-180.<br>
27. Wang CH, Cao GF, Jiang Q, Yao J: TNF-al 26. Schultz GS, Grant MB: Neovascular grown ractions. Eye (Lond) 1991, 9 (192):170-180.<br>
27. Wang CH, Cao GF, Jiang Q, Yao J: TNF-alpha promotes human retinal pigment epithelia<br>
cell migration by inducing matrix metallopep cell migration by inducing matrix metallopeptidase 9 (MMP-9) expression through activation (SEP) Act /mTORC1 signaling. *Biochem Biophys Res Commun* 2012, 425(1):33-38.<br>
28. Ni Y, Qin Y, Huang Z, Liu F, Zhang S, Zhang Z: D 41 Atter Mondel migration by S. Atter Migration by S. Atter Migration by S. Atter Migration by the S. Atter 2012, 425(1):33-38.<br>
560 28. Ni Y, Qin Y, Huang Z, Liu F, Zhang S, Zhang Z: Distinct Serum and Vitreous Inflammati ENTERTIFY AND EVALUATE SUBSIDED AND THE PROTHER SERVIT SERVIT SERVIT SERVIT SERVIT SERVIT SERVIT SERVIT SERVIT<br>
561 Factor Profiles in Patients with Proliferative Vitreoretinopathy. Adv Ther 20<br>
562 29. Limb GA, Alam A, Ea Factor Profiles in Patients with Proliferative Vitreoretinopathy. Adv Ther 2020, 37(5):2550-2559<br>
562 29. Limb GA, Alam A, Earley O, Green W, Chignell AH, Dumonde DC: Distribution of cytokine<br>
563 proteins within epiretina Factor Fromes in Fatents with Fromerative Vitreoretinopathy. Adv Ther 2020, 37(3):2550-2559.<br>
562 Limb GA, Alam A, Earley O, Green W, Chignell AH, Dumonde DC: Distribution of cytokine<br>
proteins within epiretinal membranes proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr Eye Res 1994<br>
13(11):791-798.<br>
Boles NC, Fernandes M, Swigut T, Srinivasan R, Schiff L, Rada-Iglesias A, Wang Q, Saini JS,<br>
Seconded DC: Expleme 564 13(11):791-798.<br>564 13(11):791-798.<br>565 30. Boles NC, Fernandes M, Swigut T, Srinivasan R, Schiff L, Rada-Iglesias A, Wang Q, Saini JS, Kie<br>566 Stern JH *et al*: Epigenomic and Transcriptomic Changes During Human RPE E 565 30. Boles NC, Fernar<br>
566 Stern JH *et al*: Ep<br>
567 Model of Epiretii<br>
568 2020, 14(4):631-566 Stern JH *et al:* Epigenomic and Transcriptomic Changes During Human RPE EMT in a Stem Cell<br>
Model of Epiretinal Membrane Pathogenesis and Prevention by Nicotinamide. *Stem Cell Reports*<br>
2020, 14(4):631-647. Stern Jir et al. Epigenomic and Transcriptomic Changes During Human RPE EMT in a Stem Cell<br>567 Model of Epiretinal Membrane Pathogenesis and Prevention by Nicotinamide. *Stem Cell Report*<br>2020, 14(4):631-647. 568 Model of Epiretinal Membrane Pathogenesis and Prevention by Mediatrimac. Stem Cell Reports<br>2020, 14(4):631-647. 568 2020, 14(4):631-647.



---<br>611

- Figures and legends<br>613 **Figure 1:** Perivascular<br>614 **patients with MacTel.**<br>615 **Longitudinal courses of** Figure 1: Perivascular accumulation of pigment plaques decreases vascular leakage in<br>
patients with MacTel.<br>
Longitudinal courses of three exemplary eyes showing a de novo formation of<br>
perivascular pigment plaques, imaged
- 
- 914 patients with MacTel.<br>15 Longitudinal courses<br>166 perivascular pigment<br>1617 autofluorescence (BA Longitudinal courses of three exemplary eyes showing a de novo formation of<br>616 perivascular pigment plaques, imaged with color fundus photography (CFP), b<br>617 autofluorescence (BAF), and fundus fluorescein angiography (FF
- 
- eta perivascular pigment plaques, imaged with color fundus photography (CFP), blue-light<br>autofluorescence (BAF), and fundus fluorescein angiography (FFA; early to<br>intermediate phase and late phase). A decrease in fluoresce autofluorescence (BAF), and fundus fluorescein angiography (FFA; early to<br>618 intermediate phase and late phase). A decrease in fluorescein leakage can<br>619 in vessels covered with pigment (yellow borderline), while vessels intermediate phase and late phase). A decrease in fluorescein leakage can be observed<br>in vessels covered with pigment (yellow borderline), while vessels lacking pigment may<br>show an increase in leakage and proliferation (bl
- 619 in vessels covered with pigment (yellow borderline), while vessels lacking pigment may<br>620 show an increase in leakage and proliferation (blue borderline). The right column<br>621 illustrates enlarged BAF and FFA images o
- 
- 620 show an increase in leakage and proliferation (blue borderline). The right column<br>illustrates enlarged BAF and FFA images of case #2 within the temporal and nasa<br>parafovea, respectively.<br>623 621 illustrates enlarged BAF and FFA images of case #2 within the temporal and nasal<br>622 parafovea, respectively.<br>623 **Figure 2:** Perivascular pigment accumulation stabilizes vessel growth and decreas
- 
- 
- 622 parafovea, respectively.<br>623<br>624 **Figure 2:** Perivascular p<br>625 peovascular exudation ir ---<br>624<br>625<br>626
- Figure 2: Perivascular pigment accumulation stabilizes vessel growth and decreases<br>neovascular exudation in eyes with MacTel.<br>Longitudinal courses of exemplary eyes with (cases 1-3) and without (cases 4-6) a *de*<br>novo deve neovascular exudation in eyes with MacTel.<br>626 Longitudinal courses of exemplary eyes with<br>627 novo development of pigment plaques. Periv<br>628 associated with a decrease in fluorescein lea Longitudinal courses of exemplary eyes with (cases 1-3) and without (cases 4-6) a *de*<br> *novo* development of pigment plaques. Perivascular pigment accumulation is<br>
associated with a decrease in fluorescein leakage on fund *novo* development of pigment plaques. Perivascular pigment accumulation is<br>628 associated with a decrease in fluorescein leakage on fundus fluorescein angio<br>629 (FFA), and overall stable findings on spectral domain-optica associated with a decrease in fluorescein leakage on fundus fluorescein angiography<br>
(FFA), and overall stable findings on spectral domain-optical coherence tomography<br>
(SD-OCT). Note the increase in intraretinal hyper-ref (FFA), and overall stable findings on spectral domain-optical coherence tomography<br>
(SD-OCT). Note the increase in intraretinal hyper-reflectivity (black arrowheads) with<br>
shadowing of underlying structures (white arrowhea (SD-OCT). Note the increase in intraretinal hyper-reflectivity (black arrowheads) with<br>shadowing of underlying structures (white arrowheads) associated with pigment<br>accumulation. Eyes without pigmentary changes show an inc shadowing of underlying structures (white arrowheads) associated with pigment<br>accumulation. Eyes without pigmentary changes show an increase in fluoresceir<br>leakage that may be associated with the *de novo* development of e 632 accumulation. Eyes without pigmentary changes show an increase in fluorescein<br>633 leakage that may be associated with the *de novo* development of exudative<br>factor of example associated with the *de novo* development o 633 leakage that may be associated with the *de novo* development of exudative

neovascularization (white arrowheads). Hemorrhages may occur. CFP: color fundus<br>photography.<br>636<br>637 **Figure 3:** The VldIr knockout mouse model mirrors vascular and pigmentary changes

635 photography.<br>636<br>637 **Figure 3:** The<br><sup>638</sup> observed in M ---<br>637<br>638<br>639

Figure 3: The Vldlr knockout mouse model mirrors vascular and pigmentary changes<br>638 observed in MacTel.<br>639 A: Proliferating vessels trigger perivascular pigment accumulation in Vldlr-/- mice.<br>640 Neovascular (NV) tufts a 638 observed in MacTel.<br>639 A: Proliferating vesse<br>640 Neovascular (NV) tuf<br>641 GS-lectin staining an 639 A: Proliferating vessels trigger perivascular pigment accumulation in VIdIr-/- mice.<br>640 Neovascular (NV) tufts and perivascular pigment accumulation were analyzed usir<br>641 GS-lectin staining and bright field images in Reovascular (NV) tufts and perivascular pigment accumulation were analyzed using<br>641 GS-lectin staining and bright field images in P28 VIdIr-/- mice treated with intravitreal<br>642 injections of anti-VEGF (n=6) or control I 641 GS-lectin staining and bright field images in P28 VldIr-/- mice treated with intravitreal<br>642 injections of anti-VEGF (n=6) or control IgG (n=4) at P12. While anti-VEGF treatment<br>643 significantly decreased the total n 642 injections of anti-VEGF (n=6) or control IgG (n=4) at P12. While anti-VEGF treatment<br>
significantly decreased the total number of NV-tufts (Mann-Whitney test, \*p=0.019), th<br>
ratio of pigmented to non-pigmented NV-tuft significantly decreased the total number of NV-tufts (Mann-Whitney test, \*p=0.019), the<br>ratio of pigmented to non-pigmented NV-tufts was unchanged. Pigment plaques only<br>developed along proliferating vessels. Error bars ind ratio of pigmented to non-pigmented NV-tufts was unchanged. Pigment plaques only<br>developed along proliferating vessels. Error bars indicate the median and interquartile<br>range. B: Regulation of different genes coding for ke developed along proliferating vessels. Error bars indicate the median and interquartile<br>
range. B: Regulation of different genes coding for key molecules and inducers of<br>
epithelial-mesenchymal transition (EMT) in the reti range. B: Regulation of different genes coding for key molecules and inducers of<br>epithelial-mesenchymal transition (EMT) in the retina and RPE of Vldlr-/- mice at P<br>Changes in genes between Vldlr-/- and Vldlr-/+ mice, as a epithelial-mesenchymal transition (EMT) in the retina and RPE of VIdIr-/- mice at P42.<br>
Changes in genes between VIdIr-/- and VIdIr-/+ mice, as analyzed using a PCR array<br>
for EMT, are shown. P values were calculated based 648 Changes in genes between Vldlr–/– and Vldlr-/+ mice, as analyzed using a PCR array<br>649 for EMT, are shown. P values were calculated based on a Mann-Whitney test of the<br>650 replicate 2(-Delta Ct) values for each gene i 649 for EMT, are shown. P values were calculated based on a Mann-Whitney test of the<br>650 replicate 2(-Delta Ct) values for each gene in the Vldlr-/- and Vldlr-/+ groups. \*P < 0.0<br>651 \*\*P < 0.01 (n=5 each). Median and IQR eso replicate 2(-Delta Ct) values for each gene in the Vldlr-/- and Vldlr-/+ groups. \*P < 0.05,<br>  $**P < 0.01$  (n=5 each). Median and IQR are shown for each gene. C: Dextran-<br>
angiography in a 12-months-old Vldlr-/- mouse de  $*P < 0.01$  (n=5 each). Median and IQR are shown for each gene. C: Dextran-<br>angiography in a 12-months-old VIdIr-/- mouse depicts vessel and pigment pro<br>and migration of pigmented cells along retinal vessels. Vessels cover angiography in a 12-months-old Vldlr-/- mouse depicts vessel and pigment proliferation<br>and migration of pigmented cells along retinal vessels. Vessels covered with pigment<br>show reduced dextran leakage (enlarged images, yel and migration of pigmented cells along retinal vessels. Vessels covered with pigment<br>
show reduced dextran leakage (enlarged images, yellow arrowheads) compared to<br>
stass wessels not covered with pigment (white arrowheads) 654 show reduced dextran leakage (enlarged images, yellow arrowheads) compared to<br>655 vessels not covered with pigment (white arrowheads). D: Pigment plaques cover<br>656 proliferating vessels (stained with GS-lectin) and exp ess vessels not covered with pigment (white arrowheads). D: Pigment plaques cover<br>proliferating vessels (stained with GS-lectin) and express ZO-1, indicating the form<br>form of the form 656 proliferating vessels (stained with GS-lectin) and express ZO-1, indicating the formation<br>27<br>27 657 of tight junctions along subretinal and retinal vessels in eyes of 10-months-old Vldlr-/-<br>658 mice. E: Vldlr knockout (vldlr-/-) mice show hyper-reflective changes at the level of the<br>659 outer retina (yellow arrowhead mice. E: Vldlr knockout (vldlr-/-) mice show hyper-reflective changes at the level of the<br>
outer retina (yellow arrowheads)/ retinal pigment epithelium (RPE; black arrowheads)<br>
on optical coherence tomography that resemble outer retina (yellow arrowheads)/ retinal pigment epithelium (RPE; black arrowheads)<br>on optical coherence tomography that resemble alterations observed in MacTel.<br>**Figure 4:** Inhibition of epithelial-mesenchymal-transition on optical coherence tomography that resemble alterations observed in MacTel.<br> **Figure 4:** Inhibition of epithelial-mesenchymal-transition (EMT) leads to enhance<br>
neovascular proliferation and leak in the VIdIr-/- model.<br> Figure 4: Inhibition of epithelial-mesenchymal-transition (EMT) leads to enhanced<br>neovascular proliferation and leak in the VIdIr-/- model.<br>A-C: Dextran angiography and GS lectin staining in flat mounted (A, upper panel) c neovascular proliferation and leak in the VIdIr-/- model.<br>663 A-C: Dextran angiography and GS lectin staining in flat<br>664 cryo-sectioned (A, middle and lower panel) VIdIr-/- mice<br>665 injections of neutralizing antibodies a A-C: Dextran angiography and GS lectin staining in flat mounted (A, upper panel) or<br>664 cryo-sectioned (A, middle and lower panel) Vldlr-/- mice treated with intravitreal<br>665 injections of neutralizing antibodies against T cryo-sectioned (A, middle and lower panel) Vldlr-/- mice treated with intravitreal<br>injections of neutralizing antibodies against TNFa (n=7) or FGF2 (n=7) at P21 sl<br>significant increase in dextran leakage (A, upper panel; C injections of neutralizing antibodies against TNFa (n=7) or FGF2 (n=7) at P21 showed a<br>significant increase in dextran leakage (A, upper panel; C), and a significant increase in<br>size of neovascular (NV) complexes (B) at P significant increase in dextran leakage (A, upper panel; C), and a significant increase in<br>size of neovascular (NV) complexes (B) at P42 compared to IgG-treated controls (n=7).<br>Yellow-dotted boxes in A (upper panel) show e size of neovascular (NV) complexes (B) at P42 compared to IgG-treated controls (n=7).<br>668 Yellow-dotted boxes in A (upper panel) show enlarged neovascular complexes in<br>669 treated eyes.<br>670 GS-lectin staining and bright fi Yellow-dotted boxes in A (upper panel) show enlarged neovascular complexes in<br>treated eyes.<br>GS-lectin staining and bright field images of cryo-sectioned Vldlr-/- (A, middle and<br>671 panel) illustrate decreased pigment proli 669 treated eyes.<br>670 GS-lectin stail<br>671 panel) illustrat<br>672 treated with a 670 GS-lectin staining and bright field images of cryo-sectioned VldIr-/- (A, middle and lower<br>671 panel) illustrate decreased pigment proliferation and perivascular accumulation in eyes<br>672 treated with anti-TNFa or antipanel) illustrate decreased pigment proliferation and perivascular accumulation in eyes<br>treated with anti-TNFa or anti-FGF2. D: Dextran-leakage (number of pixels positive for<br>dextran) was negatively correlated (Pearson r=treated with anti-TNFa or anti-FGF2. D: Dextran-leakage (number of pixels positive for<br>dextran) was negatively correlated (Pearson r=-0.78; p<0.0001) with pigment<br>accumulation (number of pixels positive for pigment) in fla dextran) was negatively correlated (Pearson r=-0.78; p<0.0001) with pigment<br>accumulation (number of pixels positive for pigment) in flat-mounted Vldlr-/- ey<br>F: Changes in genes coding for key molecules of EMT in Vldlr-/- m accumulation (number of pixels positive for pigment) in flat-mounted Vldlr-/- eyes. E and<br>
F: Changes in genes coding for key molecules of EMT in Vldlr-/- mice at P42 treated<br>
with either anti-TNFa (E) or anti-FGF2 (F) com 675 F: Changes in genes coding for key molecules of EMT in Vldlr–/– mice at P42 treated<br>with either anti-TNFa (E) or anti-FGF2 (F) compared to IgG-treated Vldlr-/- mice<br>(treatment at P21), as analyzed using a PCR array for 676 with either anti-TNFa (E) or anti-FGF2 (F) compared to IgG-treated VIdIr-/- mice<br>677 (treatment at P21), as analyzed using a PCR array for EMT, are shown. While<br>678 mesenchymal key molecules (white bars) were downregul

- 
- 677 (treatment at P21), as analyzed using a PCR array for EMT, are shown. While<br>mesenchymal key molecules (white bars) were downregulated, epithelial key m<br>mesenchymal key molecules (white bars) were downregulated, epithel 678 mesenchymal key molecules (white bars) were downregulated, epithelial key molecules



---<br>696<br>697 Fable 1: Clinical findings in the study cohort of patients with macular telangiectasia type<br>
2 (MacTel).<br>
Pigment No pigment Statistical<br>
Pigment No pigment Statistical<br>
Pigment Pigment Statistical<br>
Pigment Statistical<br>
Pi





698

\*p-values were calculated based on an unpaired t-test with Welch's correction.<br>
\*\*p-values were calculated based on a Fisher's exact test.<br>
701<br>
702

699<br>700<br>701<br>702 \*\*p-values were calculated based on a Fisher's exact test.

702<br>1

- 703 **Supplement:**<br>704 Supplementar<br>705 retinal-choroid<br>706 Multimodal.ret 704 Supplementary Figure 1: Pigment accumulates along proliferating retinal vessels and<br>705 retinal-choroidal anastomoses in eyes with MacTel.<br>706 Multimodal retinal images of four exemplary eyes with MacTel, including opt
- 
- 
- retinal-choroidal anastomoses in eyes with MacTel.<br>706 Multimodal retinal images of four exemplary eyes wi<br>707 Coherence tomography-angiography (enface scans<br>708 Whole retina, superficial retinal plexus, deep retinal p Multimodal retinal images of four exemplary eyes with MacTel, including optical<br>
coherence tomography-angiography (enface scans of the following layers are sh<br>
whole retina, superficial retinal plexus, deep retinal plexus
- 
- coherence tomography-angiography (enface scans of the following layers are shown:<br>
708 whole retina, superficial retinal plexus, deep retinal plexus and whole eye scans;<br>
709 vessels forming retinal-retinal and retinal-cho
- 
- whole retina, superficial retinal plexus, deep retinal plexus and whole eye scans;<br>vessels forming retinal-retinal and retinal-choroidal anastomoses are marked in re<br>scan Spectral domain (SD-) OCT, color fundus photographs vessels forming retinal-retinal and retinal-choroidal anastomoses are marked in red), B-<br>5210 scan Spectral domain (SD-) OCT, color fundus photographs (CFP), blue-light<br>5211 autofluorescence (BAF), and fundus fluorescein a 711 autofluorescence (BAF), and fundus fluorescein angiograms (FFA, late phase). Pigment<br>plaques are indicated with arrow heads. On OCT, pigment plaques depict as hyper-<br>reflective lesions. Horizontal lines on CFP images i
- scan Spectral domain (SD-) OCT, color fundus photographs (CFP), blue-light<br>
211 autofluorescence (BAF), and fundus fluorescein angiograms (FFA, late phase<br>
212 plaques are indicated with arrow heads. On OCT, pigment plaque
- plaques are indicated with arrow heads. On OCT, pigment plaques depict as hyper-<br>T13 reflective lesions. Horizontal lines on CFP images indicate the position of each B-sc<br>T14 Supplementary Figure 2: Dense intraretinal pigm

- reflective lesions. Horizontal lines on CFP images indicate the position of each B-scan.<br>714<br>715 Supplementary Figure 2: Dense intraretinal pigment plaques express the retinal pigmen<br>716 Aprithelium marker Cytokeratin-18 ( --<br>715<br>716<br>717 715 Supplementary Figure 2: Dense intraretinal pigment plaques express the retinal pigment<br>716 epithelium marker Cytokeratin-18 (CK-18).<br>717 Immunofluorescence imaging of retinal sections of 11-months-old Vldlr-/- mice wit
- 
- 
- epithelium marker Cytokeratin-18 (CK-18).<br>717 Immunofluorescence imaging of retinal sec<br>718 Iectin (red) and CK-18, alpha-smooth musc<br>719 Nuclei are shown in blue (DAPI). Intraretina 717 Immunofluorescence imaging of retinal sections of 11-months-old VIdIr-/- mice with GS-<br>718 lectin (red) and CK-18, alpha-smooth muscle actin (a-SMA), IBA-1 or RPE65 (green).<br>719 Nuclei are shown in blue (DAPI). Intrare 718 lectin (red) and CK-18, alpha-smooth muscle actin (a-SMA), IBA-1 or RPE65 (green).<br>719 Nuclei are shown in blue (DAPI). Intraretinal pigment co-locates with CK-18, but not w<br>720 a-SMA, IBA1 or RPE65. 719 Nuclei are shown in blue (DAPI). Intraretinal pigment co-locates with CK-18, but not with<br>720 a-SMA, IBA1 or RPE65.<br>721 Supplementary Figure 3: RPF-cells form clusters around peovessels within the

- 720 a-SMA, IBA1 or RPE65.<br>721<br>722 Supplementary Figure 3:<br>723 subretinal space, and exi 722 Supplementary Figure 3: RPE-cells form clusters around neovessels within the<br>
523 subretinal space, and express epithelial and mesenchymal markers.<br>
523 subretinal space, and express epithelial and mesenchymal markers.
- ---<br>722<br>723 %723 subretinal space, and express epithelial and mesenchymal markers.<br>
Subretinal space, and express epithelial and mesenchymal markers.

- 
- 
- 
- Dense intraretinal pigment plaques (along vessels of the deep plexus) express the RPE<br>
marker Cytokeratin-18 (CK-18), but not RPE65. The expression of a-SMA was<br>
observed in single pigmented intraretinal lesions (black arr marker Cytokeratin-18 (CK-18), but not RPE65. The expression of a-SMA was<br>
observed in single pigmented intraretinal lesions (black arrowhead). The latter<br>
appeared, however, overall less dense compared to those lesions la observed in single pigmented intraretinal lesions (black arrowhead). The latter<br>
127 appeared, however, overall less dense compared to those lesions lacking a-SN<br>
128 expression (white arrowhead). Immunofluorescence imagin
- 277 appeared, however, overall less dense compared to those lesions lacking a-SMA<br>278 expression (white arrowhead). Immunofluorescence imaging of flat mounted retina<br>279 12-months-old VIdIr-/- mice with GS-lectin (red) and
- expression (white arrowhead). Immunofluorescence imaging of flat mounted retinas of<br>12-months-old VldIr-/- mice with GS-lectin (red) and CK-18, alpha-smooth muscle actin<br>(a-SMA), IBA-1 or RPE65 (green). Nuclei are shown in 729 12-months-old Vldlr-/- mice with GS-lectin (red) and CK-18, alpha-smooth muscle actin<br>730 (a-SMA), IBA-1 or RPE65 (green). Nuclei are shown in blue (DAPI).<br>731<br>732
- 730 (a-SMA), IBA-1 or RPE65 (green). Nuclei are shown in blue (DAPI).<br>731<br>732<br>733
- 
- 
- 
- 732<br>733<br>734 733<br>734 733









